pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Oncology

Sep 28, 2023

PIC Therapeutics Expands its Team with the Addition of Translational Biology Oncology Leader, Richard Gedrich, PhD as Chief Development Officer

Sep 28, 2023

First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors

Sep 27, 2023

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting

Sep 27, 2023

Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Sep 27, 2023

Venatorx Pharmaceuticals to Present at IDWeek 2023

Sep 26, 2023

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 21, 2023

AffyImmune Therapeutics Named 2023 Scrip Award Finalist for Best Oncology RandD Advance

Sep 18, 2023

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Sep 18, 2023

FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN) May Proceed

Sep 18, 2023

LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer

Sep 15, 2023

Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It

Sep 13, 2023

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Sep 11, 2023

AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023

Sep 7, 2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3

Sep 6, 2023

Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines

Sep 5, 2023

CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations

Sep 5, 2023

Phanes Therapeutics Announces the Establishment of Oncology Clinical Advisory Board

Aug 22, 2023

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer

Aug 10, 2023

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Aug 10, 2023

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa

Aug 9, 2023

AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives

Aug 8, 2023

Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death

Aug 2, 2023

CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline

Aug 1, 2023

AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs

Jul 27, 2023

Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients

Jul 25, 2023

Epsilogen Announces Successful Completion of First Ever Clinical Trial of an IgE Antibody; Phase I Data for MOv18 IgE Demonstrates Potential of IgE Therapy in Cancer

Jul 24, 2023

CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC

Jul 20, 2023

Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial

Jul 19, 2023

KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million

Jul 18, 2023

Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™

Jul 13, 2023

KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer

Jul 13, 2023

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology

Jul 12, 2023

BPGbio Announces Partnership with Grupo Terralpe to Offer Groundbreaking AI-Discovered Prostate Cancer Diagnostic Test in Mexico

Jul 10, 2023

First Safety and Efficacy Data of Rakuten Medical's Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer Presented at AHNS 2023

Jul 10, 2023

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Jul 6, 2023

Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States

Jun 30, 2023

Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023 USA - English APAC - English

Jun 30, 2023

Toragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer

Jun 29, 2023

Bexion Pharmaceuticals, Inc. to Present at the ESMO World Congress on Gastrointestinal Cancer 2023

Jun 29, 2023

Liver Cancer Market to Proliferate Positively, Assesses DelveInsight | Key Companies Active in the Domain - SOTIO, GlaxoSmithKline, Pfizer, Merck, Takeda, Genentech, Boehringer Ingelheim, DNAtrix, Celldex

Jun 27, 2023

CancerVAX Reports Significant Progress on Universal Cancer Vaccine Development at UCLA

Jun 26, 2023

Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics

Jun 23, 2023

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

Jun 15, 2023

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Jun 15, 2023

AKTIS ONCOLOGY EXPANDS SCIENTIFIC ADVISORY BOARD TO ADVANCE PIPELINE OF TARGETED ALPHA RADIOPHARMACEUTICALS

Jun 15, 2023

Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio Danmark - English USA - English Danmark - Dansk

Jun 13, 2023

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

Jun 12, 2023

CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

Jun 6, 2023

AKTIS ONCOLOGY TO PARTICIPATE IN JEFFERIES HEALTHCARE CONFERENCE

Jun 6, 2023

Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023

Jun 6, 2023

Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS T-Cell Therapy in Pediatric Liver Cancer

Jun 6, 2023

CancerVAX CEO Ryan Davies and Raymond Vennare Discuss the Cancer Fighting Role of Universities

Jun 5, 2023

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities

Jun 5, 2023

Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer

Jun 5, 2023

NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 5, 2023

Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting USA - English APAC - English

Jun 5, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Jun 3, 2023

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

Jun 2, 2023

Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

Jun 1, 2023

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Jun 1, 2023

Bold Therapeutics to Present Positive Interim Gastric and Biliary Tract Cancer Results at ASCO 2023 Annual Meeting

Jun 1, 2023

Shasqi Announces Research Collaboration to Transform Targeted Cancer Treatment

May 31, 2023

Cartography Biosciences Expands Scientific Advisory Board with Leading Antibody and Bi-specific Experts

May 30, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2023

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

May 25, 2023

Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023

AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023

Cartography Biosciences Appoints Industry Veteran as Chief Administrative and Legal Officer

May 23, 2023

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

May 22, 2023

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India

May 22, 2023

Therapeutic Solutions International Spin-Off Res Nova Bio Leverages FDA Cleared Tumor Blood Vessel Targeting Technology to Intravenously Deliver Cancer Killing Viruses

May 22, 2023

Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub and Collaborations with Leading Experts in Protein Design and Cancer Immunotherapy

May 22, 2023

BPGbio Announces New Partnership with DoD Focused on AI-Guided Breast Cancer Diagnostics

May 17, 2023

Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

May 16, 2023

Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer

May 16, 2023

Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda in Patients with Advanced Refractory Melanoma at Duke Cancer Institute

May 16, 2023

ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting

May 15, 2023

Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™

May 12, 2023

AKTIS ONCOLOGY TO PARTICIPATE IN 2023 GUGGENHEIM HEALTHCARE TALKS: RADIOPHARMACEUTICALS DAY

May 10, 2023

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors

May 9, 2023

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification

May 4, 2023

SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology USA - English USA - English

May 2, 2023

Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors

May 1, 2023

CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA (pembrolizumab) in BCG-Unresponsive NMIBC

May 1, 2023

Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO

Apr 27, 2023

OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

Apr 27, 2023

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

Apr 26, 2023

Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts

Apr 26, 2023

Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting

Apr 26, 2023

Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer

Apr 26, 2023

FORE Biotherapeutics Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 25, 2023

Turn Biotechnologies to Discuss Promise of Epigenetic Reprogramming in CAR-T Cell Therapy at World Oncology Cell Therapy Congress

Apr 24, 2023

Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting

Apr 20, 2023

Edison Oncology Announces Presentation of Two Scientific Posters at AACR Annual Meeting

Apr 20, 2023

Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate

Apr 19, 2023

Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101

Apr 19, 2023

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

Apr 19, 2023

Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 18, 2023

Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023

Apr 18, 2023

EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 18, 2023

Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 18, 2023

Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023

Apr 18, 2023

Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting

Apr 17, 2023

Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023

Apr 17, 2023

Dragonfly Therapeutics Announces the Publication of Preclinical Data Supporting DF6002, its Extended Half-life IL-12 Cytokine, as A Promising Treatment for Cancer USA - English USA - English USA - Deutsch USA - español USA - Français

Apr 17, 2023

Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Apr 17, 2023

PIC Therapeutics Presents Pre-Clinical Data Update on eIF4E Regulators at AACR Annual Meeting 2023

Apr 16, 2023

Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 16, 2023

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Apr 15, 2023

Bexion Pharmaceuticals, Inc. to Present at the 2023 American Association for Cancer Research (AACR) Annual Meeting and the International Ceramide Conference (ICC)

Apr 14, 2023

Flamingo Therapeutics Announces Poster Presentation on FTX-001 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Apr 14, 2023

MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting

Apr 14, 2023

Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 14, 2023

Araris Biotech AG Presents Preclinical Data Highlighting Stable and Efficacious Low Drug-Load ADCs at American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 13, 2023

Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare's Precision Oncology Pipeline

Apr 13, 2023

Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023

Apr 13, 2023

Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Apr 13, 2023

Affini-T Therapeutics Announces Licensing Agreement with Leading Comprehensive Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Apr 13, 2023

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 12, 2023

BPGbio Announces Oncology Drug Pipeline and Prostate Cancer Biomarker Developments at AACR

Apr 12, 2023

Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs

Apr 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting

Apr 12, 2023

CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist

Apr 11, 2023

Boundless Bio to Present at the Stifel 2023 Virtual Targeted Oncology Days

Apr 11, 2023

Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Apr 11, 2023

MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

Apr 11, 2023

Elucida Oncology to Present New Clinical and Preclinical Data at the 2023 AACR Annual Meeting

Apr 10, 2023

Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting

Apr 6, 2023

Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 6, 2023

Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 5, 2023

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets

Apr 4, 2023

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer

Apr 3, 2023

Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer

Mar 31, 2023

Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China USA - English APAC - English USA - English USA - Deutsch USA - español

Mar 31, 2023

Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China USA - English APAC - English USA - Deutsch USA - Français USA - English USA - español

Mar 31, 2023

Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

Mar 31, 2023

Ablaze Pharmaceuticals compte développer une radiothérapie ciblée innovante ciblant le GPC3 et destinée à traiter le cancer du foie en Grande Chine USA - Français APAC - English USA - English USA - Deutsch USA - English USA - español

Mar 30, 2023

Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics

Mar 29, 2023

Wugen to Present Data on WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 29, 2023

Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer

Mar 29, 2023

Synthetic mRNA Market for Cancer Treatment size to grow at a CAGR of 13.4% by 2029: Growth opportunities led by BioNTech SE, Moderna Inc., CureVac AG, eTheRNA immunotherapies NV - Brandessence Market Research

Mar 28, 2023

Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy

Mar 27, 2023

OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care

Mar 24, 2023

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 23, 2023

Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer

Mar 23, 2023

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting

Mar 22, 2023

Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023

Mar 21, 2023

RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer

Mar 21, 2023

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer

Mar 20, 2023

CancerVAX CEO Ryan Davies Sits Down with Oncology Research Leader

Mar 17, 2023

CancerVax Universal Cancer Vaccine Being Developed by UCLA

Mar 16, 2023

Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 16, 2023

CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine

Mar 16, 2023

ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

Mar 15, 2023

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2023

Mar 15, 2023

Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 USA - English APAC - English

Mar 15, 2023

OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 15, 2023

Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway

Mar 15, 2023

Sermonix Pharmaceuticals Announces E-Poster Presentation on I-SPY 2 Study of Neoadjuvant Lasofoxifene at St. Gallen International Breast Cancer Conference 2023

Mar 14, 2023

Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute

Mar 14, 2023

Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 14, 2023

Nitrase Therapeutics to Present at the 2023 American Association for Cancer Research Annual Meeting

Mar 9, 2023

Prestige Biopharma Develops First-in-Class PAUF-detecting Diagnostic Kit, a Powerful Tool for Early Detection of Pancreatic Cancer

Mar 9, 2023

Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy

Mar 8, 2023

Nature Paper from PACT Pharma and UCLA Highlights How Patients with Cancer Respond Differently to Anti-PD-1 Therapy

Mar 8, 2023

Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute

Mar 7, 2023

Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-cell Leukemia

Mar 7, 2023

MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment

Mar 7, 2023

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

Mar 6, 2023

Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using FloraStilbene™ Immune Stimulator Through Res Nova Bio Subsidiary

Mar 6, 2023

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001

Mar 6, 2023

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Mar 6, 2023

Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer

Mar 6, 2023

AKTIS ONCOLOGY TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE

Mar 6, 2023

Virion Therapeutics Presents Promising Preclinical Cancer Data When Using a Novel Genetically Encoded Checkpoint Modifier-Based Immunotherapy

Mar 6, 2023

Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

Mar 2, 2023

Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology

Mar 2, 2023

Kartos Therapeutics Appoints Dr. Srdan Verstovsek as Chief Medical Officer

Mar 2, 2023

SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer

Feb 28, 2023

Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer

Feb 23, 2023

Peel Therapeutics Closes New Financing Round and Expands Board of Directors to Support Evolution-Based Medicines for Cancer and Inflammation

Feb 23, 2023

Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer

Feb 17, 2023

Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments

Feb 14, 2023

enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Feb 14, 2023

Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium

Feb 9, 2023

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

Feb 7, 2023

Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day

Feb 7, 2023

Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer

Feb 6, 2023

RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting

Feb 3, 2023

Mnemo Therapeutics and Institut Curie Announce Two Key Publications in Science Immunology Highlighting Novel Approach to Identify Unknown, Therapeutically Relevant Cancer-Specific Targets USA - English France - Français

Feb 2, 2023

Flare Therapeutics to Present at Guggenheim Healthcare Talks 2023 Oncology Day

Feb 1, 2023

Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment

Jan 31, 2023

Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy

Jan 31, 2023

Myeloid Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day

Jan 30, 2023

Therapeutic Solutions International Spin Off Res Nova Bio Announces Recruitment of President and Chief Executive Officer

Jan 26, 2023

Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day

Jan 25, 2023

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics Platform Technology

Jan 21, 2023

Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium

Jan 19, 2023

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer

Jan 19, 2023

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

Jan 19, 2023

Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care

Jan 17, 2023

Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Jan 11, 2023

Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics and Leadartis - ResearchAndMarkets.com

Jan 9, 2023

Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial Evaluating AVB-001 for the Treatment of Ovarian Cancer

Jan 9, 2023

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

Jan 5, 2023

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics

Jan 5, 2023

ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer

Jan 5, 2023

Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer

Jan 5, 2023

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

Jan 4, 2023

AKTIS ONCOLOGY TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jan 3, 2023

Elucida Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023

ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics

Dec 27, 2022

CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 27, 2022

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer

Dec 27, 2022

Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2- Breast Cancer Therapy with End-to-End AI Engine

Dec 21, 2022

Anocca secures EUR 25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer

Dec 20, 2022

MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

Dec 20, 2022

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Dec 20, 2022

iOnctura awarded EUR17.5 million funding from the EIC Accelerator for clinical development of novel pancreatic cancer therapy

Dec 19, 2022

Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene

Dec 15, 2022

MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology

Dec 14, 2022

Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer

Dec 13, 2022

MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe

Dec 13, 2022

PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer

Dec 13, 2022

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

Dec 12, 2022

ICHNOS SCIENCES PRESENTS DATA SUPPORTING THREE ONCOLOGY ASSETS AT ASH 2022 ANNUAL MEETING

Dec 12, 2022

Onchilles Pharma Nominates First Drug Development Candidate Leveraging Neutrophil Biology for the Treatment of Cancer

Dec 9, 2022

Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns

Dec 8, 2022

Oncolytics Biotech's Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium USA - English USA - English USA - English Deutschland - Deutsch

Dec 8, 2022

iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289

Dec 8, 2022

Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium

Dec 8, 2022

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice

Dec 8, 2022

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Dec 8, 2022

Context Therapeutics Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Dec 8, 2022

Oncolytics Biotech's Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Dec 6, 2022

Systems Oncology to Present Positive Preclinical Data for SERA2 at J.P. Morgan 41st Annual Healthcare Conference

Dec 6, 2022

Candel Therapeutics RandD Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

Dec 1, 2022

Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI

Nov 30, 2022

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Nov 29, 2022

AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress

Nov 29, 2022

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

Nov 28, 2022

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

Nov 22, 2022

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer

Nov 21, 2022

Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium

Nov 21, 2022

FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers

Nov 17, 2022

Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium

Nov 17, 2022

ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer

Nov 15, 2022

Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer

Nov 15, 2022

CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline

Nov 15, 2022

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

Nov 15, 2022

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

Nov 14, 2022

OncoNano Medicine Announces New Preclinical Data for ON-BOARD™ Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 11, 2022

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

Nov 11, 2022

Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting

Nov 10, 2022

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2022

PACT Pharma Reports Data From First Clinical Study Using CRISPR to Substitute a Gene in Patients' Immune Cells to Treat Cancer

Nov 10, 2022

Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2022

Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 10, 2022

Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies

Nov 10, 2022

Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors

Nov 10, 2022

Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types

Nov 10, 2022

Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer

Nov 10, 2022

CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin

Nov 10, 2022

OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 10, 2022

Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 10, 2022

CytoImmune Therapeutics to Present Preclinical Data Highlighting Potential of Novel TRACK-NK Cells to Selectively Target and Kill Hematologic and Solid Tumor Cancer Cells

Nov 10, 2022

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 10, 2022

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 8, 2022

Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 8, 2022

Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors

Nov 7, 2022

Nouscom's Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors

Nov 7, 2022

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001

Nov 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Nov 7, 2022

Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Nov 7, 2022

Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial

Nov 7, 2022

Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine, BCA356, at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Nov 7, 2022

Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 7, 2022

Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy

Nov 3, 2022

Elucida Oncology to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 2, 2022

Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics

Nov 2, 2022

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 1, 2022

Carisma Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 37th Anniversary Annual Meeting

Oct 31, 2022

Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium

Oct 28, 2022

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium

Oct 27, 2022

Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 27, 2022

Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.

Oct 26, 2022

Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium

Oct 24, 2022

CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC 2022

Oct 24, 2022

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

Oct 21, 2022

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Oct 20, 2022

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

Oct 19, 2022

Avenge Bio to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 19, 2022

PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer

Oct 19, 2022

Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 18, 2022

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS T Cell Therapy for Neuroblastoma

Oct 18, 2022

Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress

Oct 14, 2022

Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers

Oct 13, 2022

Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing

Oct 12, 2022

Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC), Dec 15 - 17

Oct 12, 2022

Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs

Oct 12, 2022

Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic

Oct 12, 2022

Capstan Therapeutics Announces Appointment of Athena Countouriotis, M.D., as Board Chair and Strengthens Leadership Team with Key Appointment

Oct 11, 2022

Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 6, 2022

Shasqi Scientific Advisor Carolyn Bertozzi Awarded Nobel Prize for the Development of Click Chemistry

Oct 5, 2022

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

Oct 5, 2022

OncoNano Medicine to Present Data on Novel Development Candidates at the Society for Immunology of Cancer (SITC) Annual Meeting

Oct 4, 2022

Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets

Oct 4, 2022

Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer

Oct 3, 2022

Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection

Sep 29, 2022

Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference

Sep 29, 2022

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 29, 2022

Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting

Sep 29, 2022

With the Establishment of India Entity, Mickey Mikitani, Co-CEO of Rakuten Medical Visits Respected Medical Institutions in India

Sep 29, 2022

Meliora Therapeutics Raises $11M Seed Financing to Develop First Mechanism Of Action Atlas in Oncology

Sep 27, 2022

Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer

Sep 27, 2022

SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University

Sep 26, 2022

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U.S.

Sep 26, 2022

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

Sep 22, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference

Sep 21, 2022

Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody

Sep 21, 2022

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

Sep 21, 2022

NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma

Sep 20, 2022

Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines

Sep 19, 2022

AKTIS ONCOLOGY APPOINTS SHULAMIT RON-BIGGER AS CHIEF OPERATING OFFICER

Sep 19, 2022

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics

Sep 19, 2022

OncoNano Medicine to Present at Cantor Fitzgerald Oncology and HemOnc Conference

Sep 18, 2022

Bugworks Research Inc. et Cytecare Cancer Hospitals annoncent leur collaboration pour accélérer le développement de thérapies d'immuno-oncologie de pointe France - Français USA - English Deutschland - Deutsch USA - English

Sep 16, 2022

EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR Summit

Sep 15, 2022

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

Sep 14, 2022

Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen

Sep 13, 2022

RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications

Sep 13, 2022

RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer

Sep 13, 2022

Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

Sep 12, 2022

Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology

Sep 12, 2022

Enterome presents further efficacy data on its new generation therapeutic cancer vaccine EO2401 at ESMO Congress, demonstrating ability of OncoMimics™ antigens to generate positive clinical outcome

Sep 12, 2022

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

Sep 10, 2022

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 10, 2022

Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 9, 2022

Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors

Sep 9, 2022

Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer

Sep 8, 2022

Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022

Sep 8, 2022

Osmol Therapeutics Announces Appointment of Teresa Bitetti, President, Global Oncology Business Unit at Takeda Pharmaceuticals, to the Board of Directors

Sep 8, 2022

Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022

Sep 7, 2022

Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer USA - English USA - English USA - English

Sep 7, 2022

InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

Sep 7, 2022

Nitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology

Sep 7, 2022

SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test

Sep 7, 2022

Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer USA - English USA - English India - English Israel - English

Sep 6, 2022

Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets

Sep 6, 2022

Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress

Sep 6, 2022

Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022

Sep 6, 2022

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022

Sep 6, 2022

NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 4, 2022

Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022

Aug 29, 2022

NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER

Aug 25, 2022

AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS

Aug 23, 2022

Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers

Aug 23, 2022

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

Aug 22, 2022

PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment

Aug 22, 2022

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development

Aug 19, 2022

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer

Aug 18, 2022

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ

Aug 18, 2022

Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer

Aug 17, 2022

Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI/NIH Grant to Advance Their Lung Cancer Immunotherapy Program Using RNA-Targeting Gene Therapy with Checkpoint Inhibitors

Aug 16, 2022

Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office

Aug 10, 2022

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Aug 3, 2022

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer

Aug 2, 2022

MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)

Aug 1, 2022

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer

Jul 28, 2022

SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments

Jul 28, 2022

Step Pharma Progresses into Oncology Clinical Trials with STP938, the World’s Most Advanced CTPS1 Inhibitor

Jul 28, 2022

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist's Lab at Major US Cancer Center

Jul 28, 2022

Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade

Jul 27, 2022

Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022

Jul 27, 2022

BridGene Biosciences Announces $38.5 Million Series B Financing to Further Develop Its Next Generation Chemoproteomics Platform and First-in-Class Oncology Drugs

Jul 26, 2022

Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

Jul 19, 2022

Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research and Drug Discovery Program

Jul 18, 2022

MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer

Jul 12, 2022

Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients

Jul 11, 2022

Inspirna Raises $50 Million in Series D Financing

Jul 11, 2022

Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer

Jul 7, 2022

Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology

Jul 6, 2022

Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors

Jul 6, 2022

Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials

Jul 5, 2022

ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

Jun 30, 2022

Phanes Therapeutics' PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA

Jun 29, 2022

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

Jun 29, 2022

Ornithine Decarboxylase (ODC) Inhibitor Pipeline Insight Report 2022 Featuring Orbus Therapeutics, Aminex Therapeutics, Genzyme, Nippon Kayaku, and Cancer Prevention Pharmaceuticals - ResearchAndMarkets.com

Jun 28, 2022

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer

Jun 28, 2022

Araris Biotech AG to Present at the H.C. Wainwright Preclinical Cancer Drug Discovery Virtual Conference

Jun 27, 2022

US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510

Jun 27, 2022

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

Jun 22, 2022

Nutcracker Therapeutics Bolsters Leadership with Chief Operating Officer and Other Key Hires, Reveals Oncology Pipeline

Jun 22, 2022

Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer

Jun 21, 2022

Phanes Therapeutics' PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA

Jun 21, 2022

Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)

Jun 16, 2022

Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.

Jun 16, 2022

Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges

Jun 15, 2022

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

Jun 14, 2022

MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies

Jun 14, 2022

AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer

Jun 14, 2022

NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer

Jun 14, 2022

Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases

Jun 9, 2022

Clinique d'Oncologie 16 Novembre Becomes First Site in Africa to Deploy Varian's Ethos Therapy System for Adaptive Cancer Treatment USA - English France - Français

Jun 7, 2022

EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso for Non-Small Cell Lung Cancer

Jun 7, 2022

AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer

Jun 6, 2022

Nouscom Announces Positive Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Jun 6, 2022

Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022

Jun 6, 2022

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy

Jun 4, 2022

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Jun 3, 2022

Bicara Therapeutics Presents Data from Dose Escalation Portion of Ongoing Phase 1/1b Trial of Lead Bifunctional Program, BCA101, at the American Society of Clinical Oncology 2022 Annual Meeting

Jun 3, 2022

Elucida Oncology to Present at Two Upcoming Conferences

Jun 2, 2022

Scorpion Therapeutics Announces Discovery Scientific Advisory Board

Jun 2, 2022

Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis LW-02 Column is Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer

Jun 2, 2022

Nitrase Therapeutics Expands Pipeline to Include Oncology Programs and Adds Seasoned Cancer Experts to Scientific Advisory Board

Jun 2, 2022

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

Jun 1, 2022

OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer

Jun 1, 2022

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

Jun 1, 2022

Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly

Jun 1, 2022

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metastatic HER2-Positive Breast Cancer Patients at the ASCO 2022 Annual Meeting

Jun 1, 2022

Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting

Jun 1, 2022

Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Jun 1, 2022

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

May 31, 2022

Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting

May 31, 2022

Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS T Cells (ECT204) for Advanced Liver Cancer

May 30, 2022

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

May 29, 2022

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer

May 27, 2022

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

May 26, 2022

Biotheryx to Present Preclinical Data for Its Dual Protein Degrader BTX-1188 at the 2022 American Society of Clinical Oncology Annual Meeting

May 26, 2022

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022

Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer

May 26, 2022

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022

Worldwide Cancer Cachexia Industry to 2027 - Featuring Aphios, Artelo Biosciences and AVEO Pharmaceuticals Among Others - ResearchAndMarkets.com

May 26, 2022

Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer

May 24, 2022

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting USA - English España - español France - Français Deutschland - Deutsch

May 24, 2022

HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting

May 23, 2022

Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer

May 20, 2022

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit

May 19, 2022

Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022

May 19, 2022

Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans

May 18, 2022

Propanc Biopharma Undertaking PRP Manufacturing and Development for Human Use

May 17, 2022

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an 'Off-The-Shelf' Cancer Immunotherapy Developed using Nouscom's Proprietary Viral Vector Platform

May 16, 2022

ITM to Host Scientific Precision Oncology Symposium in Parallel to the ASCO Annual Meeting on Friday, June 03, 2022

May 16, 2022

CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

May 11, 2022

Propanc Biopharma Offers a Novel Way to Stop Cancer

May 10, 2022

MOMA Therapeutics Announces $150 Million Series B Financing

May 10, 2022

Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

May 8, 2022

Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022

May 6, 2022

Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference

May 5, 2022

AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer

May 4, 2022

Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022

May 3, 2022

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer

May 3, 2022

Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients

May 2, 2022

CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard-of-Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models

Apr 28, 2022

HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer

Apr 28, 2022

Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 27, 2022

Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 27, 2022

Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer

Apr 26, 2022

Flare Therapeutics Appoints Adrian Jubb as Chief Medical Officer

Apr 25, 2022

AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)

Apr 25, 2022

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Apr 21, 2022

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer

Apr 21, 2022

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Apr 20, 2022

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

Apr 19, 2022

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer

Apr 19, 2022

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

Apr 18, 2022

Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute

Apr 14, 2022

Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

Apr 13, 2022

Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute

Apr 13, 2022

CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Apr 13, 2022

EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer

Apr 13, 2022

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer

Apr 13, 2022

Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment

Apr 12, 2022

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

Apr 12, 2022

Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer

Apr 11, 2022

Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting

Apr 11, 2022

MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy

Apr 11, 2022

Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022

Apr 11, 2022

InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients

Apr 11, 2022

PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022

Apr 11, 2022

Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022

Apr 11, 2022

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

Apr 11, 2022

Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting

Apr 11, 2022

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways

Apr 10, 2022

Gennao Bio Presents Promising New Results from its Gene Monoclonal Antibody (GMAB) Platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Apr 10, 2022

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming

Apr 10, 2022

Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022

Apr 10, 2022

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming

Apr 9, 2022

PIC Therapeutics to Present Pre-Clinical Data on eIF4E Program to Address Breast Cancer Drug Resistance at AACR Annual Meeting 2022

Apr 8, 2022

Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022

Apr 8, 2022

Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting

Apr 8, 2022

HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022

Apr 8, 2022

Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022

Apr 8, 2022

Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022

Apr 8, 2022

Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Apr 8, 2022

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

Apr 8, 2022

BioMed Leaders: Sunshine Biopharma, PharmaDrug, Blue Water Vaccines, and MedAvail; Visionary CEOs Advancing Healthcare, with Vaccines, Cancer Therapeutics, and Affordable Pharmaceuticals

Apr 8, 2022

Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Apr 8, 2022

Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Apr 8, 2022

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Apr 7, 2022

Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting

Apr 7, 2022

REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH

Apr 7, 2022

LTZ Therapeutics Secures $17 Million Pre-Series A Financing for Immunotherapy Development to Treat Cancer and Other Complex Diseases

Apr 6, 2022

Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer USA - English USA - English USA - English

Apr 6, 2022

AffyImmune Therapeutics to Present Poster at American Association for Cancer Research Annual Meeting

Apr 6, 2022

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma

Apr 6, 2022

Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment

Apr 6, 2022

Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic

Apr 6, 2022

Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer USA - English Israel - English

Apr 6, 2022

Notch Therapeutics Welcomes Deepika Rajesh as VP, Stem Cell Biology and Developmental Immunology

Apr 5, 2022

Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors

Apr 4, 2022

Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Apr 4, 2022

Bright Peak Therapeutics kündigt mehrere Präsentationen auf der Jahrestagung der American Association for Cancer Research (AACR) an

Apr 4, 2022

Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting

Apr 4, 2022

Vivace Therapeutics to Present New Data from Preclinical Combination Studies of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022

Apr 1, 2022

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer

Mar 31, 2022

Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 30, 2022

Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 30, 2022

NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April

Mar 30, 2022

NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting

Mar 30, 2022

Accutar Biotechnology Announces First Patient Dosed with AC0176 in Phase 1 Study in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Mar 29, 2022

Shorla Oncology Appoints Dennis Purcell as Chairman of the Board of Directors

Mar 29, 2022

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

Mar 28, 2022

Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update USA - English USA - English

Mar 28, 2022

Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2022

ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

Mar 24, 2022

Oncolytics Biotech Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

Mar 24, 2022

Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform

Mar 24, 2022

Oncolytics Biotech Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort USA - Français USA - English USA - English Norge - Norsk Sverige - Svenska USA - Nederlands Suomi - Suomeksi

Mar 23, 2022

Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company

Mar 23, 2022

Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 22, 2022

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

Mar 22, 2022

ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmaceuticals

Mar 22, 2022

KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 22, 2022

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Mar 22, 2022

Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis

Mar 22, 2022

Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent and Trademark Office

Mar 21, 2022

Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board

Mar 21, 2022

Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb

Mar 21, 2022

Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting USA - English USA - English

Mar 21, 2022

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer France - Français USA - English Deutschland - Deutsch

Mar 21, 2022

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer

Mar 21, 2022

Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC™ Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 16, 2022

Phanes Therapeutics Announces Three Upcoming Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 16, 2022

KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics

Mar 15, 2022

EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting

Mar 15, 2022

Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 15, 2022

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein USA - English USA - English

Mar 15, 2022

PharmaJet Partner Immunomic Therapeutics Initiates Clinical Trial of DNA Vaccine for Skin Cancer

Mar 15, 2022

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

Mar 14, 2022

SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study

Mar 11, 2022

The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue), Published in JAMA Oncology

Mar 11, 2022

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health

Mar 10, 2022

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects

Mar 10, 2022

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation at ACRO Summit 2022 on Sensitizing Head and Neck Cancer to Radiation Using the Company’s Cerium Oxide Nanoparticles

Mar 10, 2022

NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting

Mar 10, 2022

Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR Annual Meeting: Selective Intracellular Effects Leading to Immunogenic Cell Death (ICD) in Prostate Cancer Cell Models

Mar 10, 2022

DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer

Mar 10, 2022

ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer

Mar 10, 2022

OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 10, 2022

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

Mar 9, 2022

Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy

Mar 9, 2022

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022

Mar 9, 2022

Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 9, 2022

Seneca Therapeutics Announces Publication of AACR Abstract Demonstrating Systemic Anti-Tumor Immune Response in Syngeneic Pancreatic Murine Model

Mar 9, 2022

Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress

Mar 9, 2022

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 9, 2022

Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting

Mar 9, 2022

Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 9, 2022

Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors

Mar 8, 2022

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology

Mar 8, 2022

Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022

Mar 8, 2022

HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022

Mar 8, 2022

Preclinical Data of Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Presented in ESMO TAT 2022

Mar 8, 2022

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 8, 2022

Gennao Bio Announces Oral Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English USA - English

Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English Israel - English

Mar 3, 2022

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment

Mar 3, 2022

Elucida Oncology to Present at Two Upcoming Scientific Conferences

Mar 2, 2022

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

Mar 2, 2022

Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing

Mar 2, 2022

REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER

Mar 2, 2022

Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer

Mar 1, 2022

Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer

Mar 1, 2022

NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to Patients

Feb 28, 2022

Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

Feb 28, 2022

Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of ES104 for Treatment of Colorectal Cancer

Feb 27, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Feb 25, 2022

Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors

Feb 24, 2022

GI Innovation Signs MoU With Cellkey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology

Feb 22, 2022

Boundless Bio Appoints Klaus Wagner, M.D., Ph.D., as Chief Medical Officer

Feb 22, 2022

Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO

Feb 22, 2022

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.

Feb 22, 2022

Cumulus Oncology Secures £4.1m ($5.6m) Investment Led by Eos Advisory

Feb 17, 2022

Edison Oncology Announces Treatment of First Patient in Orotecan (irinotecan HCI oral solution) Phase I/IIa Clinical Trial for Patients with Recurrent Pediatric Solid Tumors

Feb 17, 2022

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers USA - English USA - English

Feb 17, 2022

Immunicom Appoints Dr. Annette Marleau as Chief Technology Officer

Feb 17, 2022

Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth

Feb 17, 2022

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

Feb 16, 2022

Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer

Feb 15, 2022

Grey Wolf Therapeutics Announces Formation of Clinical Advisory Board in Anticipation of Advancing First-in-Class Immuno-Oncology Approach into the Clinic

Feb 15, 2022

ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin

Feb 15, 2022

Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse

Feb 14, 2022

Vivacitas Oncology to Present at the 2022 BIO CEO and Investor Conference

Feb 14, 2022

OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey Demonstrating Oncodermatology Unmet Need at ASCO GU

Feb 10, 2022

Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer

Feb 9, 2022

Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech

Feb 8, 2022

Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference

Feb 8, 2022

enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Feb 8, 2022

SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors

Feb 7, 2022

Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib Plus FOLFIRINOX As First Line Therapy for Advanced Pancreatic Cancer

Feb 7, 2022

Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline

Feb 7, 2022

Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

Feb 3, 2022

Kriya Announces the Appointment of Ma’an Muhsin, M.D., as President and Chief Medical Officer of Its Oncology Therapeutic Area Division

Feb 2, 2022

Boundless Bio to Present at the Guggenheim Oncology Conference

Feb 2, 2022

Pimera Therapeutics Awarded Grant by US Department of Defense to Evaluate PMR-116, a Novel Inhibitor of RNA Polymerase I (Pol I) Transcription, in Patients with Prostate Cancer

Feb 1, 2022

Chemical Society Reviews Journal Explores How OncoTEX’s Gold-Based Compounds Can Activate the Immune System to Fight Cancer

Jan 31, 2022

Vivacitas Oncology Strengthens Its Neuro-Oncology Board With World-Class Advisor Dr. Katherine Peters, MD, PhD, FAAN

Jan 27, 2022

Oncolytics Biotech Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Jan 27, 2022

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE PARTNERSHIP FOR METASTATIC CANCER TRIALS

Jan 25, 2022

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients

Jan 24, 2022

ITM: Installation of New Isotope Production System at Bruce Power to Produce Medical Isotopes for Cancer Therapy Completed

Jan 20, 2022

Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology

Jan 19, 2022

OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for New Cancer Therapy-Associated Diarrhea Treatments at ASCO GI 2022

Jan 18, 2022

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613 (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 18, 2022

Aktis Oncology Expands Leadership Team with Two Strategic Hires

Jan 18, 2022

Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio

Jan 18, 2022

Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit

Jan 17, 2022

Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine

Jan 13, 2022

Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets

Jan 12, 2022

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation of Data on Cerium Oxide Nanoparticles to Sensitize Radiation for Head and Neck Cancer at ACRO 2022 Summit

Jan 12, 2022

MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference

Jan 12, 2022

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Jan 11, 2022

Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb's Anti-PD-1 Opdivo USA - English USA - English

Jan 11, 2022

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

Jan 11, 2022

Curebase and Persephone Biosciences Partner in Clinical Trial of Colorectal Cancer Among Diverse Populations

Jan 10, 2022

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

Jan 10, 2022

Vivacitas Oncology to Present AR-67 at the Biotech Showcase Investor Conference

Jan 9, 2022

Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors

Jan 7, 2022

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

Jan 6, 2022

AKTIS ONCOLOGY TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jan 5, 2022

NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

Jan 5, 2022

Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones

Jan 5, 2022

Elucida Oncology to Present at Two Upcoming Investor Conferences

Jan 4, 2022

OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer Therapy Induced Skin Toxicity that Met Expectations

Jan 3, 2022

Vivacitas Oncology Welcomes Dr. Jai Grewal, MD, and Expands Its Neuro-Oncology Advisory Board

Dec 28, 2021

Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment

Dec 27, 2021

VLP Therapeutics raises $21M Series A-1 for cancer treatment vaccine, infectious diseases vaccine RandD

Dec 24, 2021

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer

Dec 23, 2021

Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform

Dec 22, 2021

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

Dec 22, 2021

CSTONE ANNONCE L'APPROBATION D'UN NOUVEAU MÉDICAMENT EN CHINE, CEJEMLY (SUGEMALIMAB), QUI POURRAIT REMODELER LE PAYSAGE DE L'IMMUNO-ONCOLOGIE DANS LE CANCER DU POUMON France - Français USA - English USA - English Brazil - Português España - español Latin America - español

Dec 20, 2021

CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Dec 15, 2021

Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering and Therapeutic Conference

Dec 15, 2021

Vivacitas Oncology Presents Its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN

Dec 15, 2021

BridGene Biosciences Announces Research Collaboration with the Peter MacCallum Cancer Centre to Discover Targets and Small Molecule Drug Candidates for Ovarian Cancer

Dec 14, 2021

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA (pembrolizumab) in Patients with Metastatic Breast Cancer

Dec 13, 2021

Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium

Dec 10, 2021

Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal

Dec 9, 2021

Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium

Dec 9, 2021

iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies

Dec 9, 2021

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Dec 9, 2021

Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer

Dec 9, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium

Dec 9, 2021

Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology

Dec 9, 2021

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer

Dec 7, 2021

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium

Dec 7, 2021

Immunicom Announces Promising Preliminary Data from its Immunopheresis Study in Late-Stage Cancer and Metastatic Melanoma Patients Presented at 2021 SITC Congress

Dec 7, 2021

Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines

Dec 2, 2021

HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical

Dec 1, 2021

enGene Announces Poster Presentation at the Society of Urologic Oncology 2021 Annual Meeting

Dec 1, 2021

National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer

Dec 1, 2021

Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition for Enhancing the Vulnerability of Cancer Cells

Dec 1, 2021

Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals

Dec 1, 2021

Accutar Biotechnology Announces First Patient Dosed with AC0682 in Phase 1 Study in Patients with ER-Positive / HER2-Negative Locally Advanced or Metastatic Breast Cancer

Nov 30, 2021

AFFPC Celebrates Giving Tuesday By Donating $200,000.00 To BERG's Project Survival

Nov 30, 2021

Vivacitas Oncology Announces Additions to Leadership Team and Board

Nov 30, 2021

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment

Nov 29, 2021

Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications

Nov 29, 2021

Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Nov 29, 2021

Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation

Nov 29, 2021

Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability

Nov 29, 2021

Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market USA - English USA - español USA - Français USA - Deutsch

Nov 29, 2021

Ablaze Pharmaceuticals lance un financement de série A de 75 millions de dollars pour apporter de nouveaux produits radiopharmaceutiques ciblés afin de traiter les patients atteints de cancer sur le marché de la Grande Chine USA - Français USA - English USA - español USA - Deutsch

Nov 24, 2021

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Nov 22, 2021

Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at the 2021 San Antonio Breast Cancer Symposium

Nov 22, 2021

Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer

Nov 17, 2021

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of ET140203 ARTEMIS T Cells to Treat Pediatric Liver Cancer

Nov 17, 2021

Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine

Nov 17, 2021

First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology

Nov 16, 2021

NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting

Nov 16, 2021

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe

Nov 16, 2021

Volastra Therapeutics Expands Leadership Team to Tackle Cancer

Nov 15, 2021

Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma

Nov 15, 2021

CORRECTING and REPLACING Penrose TherapeuTx Appoints Pharmaceutical Leader David Sherris, Ph.D., as President and Chief Executive Officer

Nov 15, 2021

NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Nov 15, 2021

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

Nov 13, 2021

CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Nov 12, 2021

MiNA Therapeutics Highlights Clinical Data Supporting the Further Development of MTL-CEBPA as an Anti-cancer Immunotherapy

Nov 12, 2021

Grey Wolf Therapeutics Presents Promising Preclinical Data on First-in-Class ERAP1 Inhibitors at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 12, 2021

Bicara Therapeutics Presents Promising New Preclinical Data for Lead Immunotherapy Program BCA101 at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Nov 12, 2021

Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting

Nov 12, 2021

Apexigen Announces New Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting

Nov 11, 2021

Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021

Nov 10, 2021

Pyxis Oncology to Present at the Jefferies London Healthcare Conference

Nov 10, 2021

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine for the treatment of MSI-H solid tumors

Nov 10, 2021

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting

Nov 9, 2021

HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals

Nov 9, 2021

HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting

Nov 9, 2021

Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Nov 9, 2021

Dragonfly Therapeutics Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

Nov 9, 2021

Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)

Nov 9, 2021

MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)

Nov 9, 2021

Codagenix to Present Promising Preclinical Data for Oncolytic Virus Therapeutic CodaLytic™ at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Nov 8, 2021

Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform

Nov 4, 2021

Enterome - Significant Progress with OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases

Nov 4, 2021

Shasqi to Present Data Updates at Upcoming SITC and CTOS Meetings

Nov 4, 2021

Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy (ipilimumab) for Treatment of Metastatic Endometrial Cancer

Nov 3, 2021

Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

Nov 3, 2021

Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November

Nov 3, 2021

Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX

Nov 2, 2021

Immunicom Conference Highlights Innovation in Clinical Trial Design to Advance its Breakthrough Cancer Immunotherapy Platform

Nov 2, 2021

Prokarium Promotes Livija Deban to Chief Scientific Officer to Drive Pipeline Expansion in Cancer Immunotherapy

Nov 2, 2021

OncoResponse Announces Initiation of Phase 1 Trial of OR2805 - Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy - in Patients with Advanced Cancer

Oct 29, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research

Oct 28, 2021

Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613 (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

Oct 28, 2021

Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Oct 28, 2021

Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies

Oct 27, 2021

Inceptor Bio Announces Agreement to Acquire Gainesville, FL GMP Facility And Transfer Operating Team From Arranta Bio To Accelerate Cell Therapies To Cure Cancer

Oct 27, 2021

XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target

Oct 26, 2021

HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19

Oct 26, 2021

Diverse Biotech Announces Its DBT-12733 Molecule Demonstrated to Be Up to 8,000 Times More Effective Than Temozolomide for Brain Cancer

Oct 25, 2021

Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation

Oct 25, 2021

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA (Pembrolizumab) for Treatment of Cancer

Oct 25, 2021

AnHeart Therapeutics Announces First Patient Dosed in Global Phase 2 TRUST-II Study for Taletrectinib in ROS1 Fusion-Positive Lung Cancer

Oct 23, 2021

OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress

Oct 21, 2021

Rakuten Medical and Karkinos Healthcare Announce Strategic Partnership to Expand the Reach of Novel Cancer Care in India

Oct 21, 2021

Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers

Oct 21, 2021

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Oct 20, 2021

NKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting

Oct 20, 2021

Crescendo Biologics Announces Prestigious New Collaboration With the Institute of Cancer Research, London

Oct 20, 2021

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine

Oct 19, 2021

ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement

Oct 18, 2021

Ipsen Adds Another Program Into Its Pre-Clinical RandD Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Oct 14, 2021

Oncolytics BiotechPartner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Oct 13, 2021

Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients

Oct 12, 2021

First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study

Oct 12, 2021

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program

Oct 12, 2021

CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Oct 12, 2021

AUM Biosciences announces closing of USD $27Million in a "Series A" Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies

Oct 11, 2021

CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 Targeting First-in-Human Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Oct 7, 2021

LIPAC Oncology Secures Broad Patent Protection for Proliposomal Paclitaxel Compositions Formulated for Delivery to the Bladder and Ureter for the Treatment of Solid Tumor Carcinomas

Oct 7, 2021

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 7, 2021

Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways

Oct 7, 2021

Boundless Bio Presents Data on Extrachromosomal DNA (ecDNA) Driven Resistance to KRASG12C Inhibitors at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Oct 7, 2021

Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy

Oct 7, 2021

BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Oct 7, 2021

Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Oct 6, 2021

Apexigen Announces First Patient Dosed in Phase 3 Pivotal Trial for BD0801, an Anti-VEGF Monoclonal Antibody, in Combination Therapy for Ovarian Cancer

Oct 6, 2021

PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer

Oct 6, 2021

Step Pharma Appoints Experienced Cancer Drug Developer Adrian Senderowicz to Board of Directors

Oct 5, 2021

Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients USA - English USA - English USA - English

Oct 5, 2021

Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 5, 2021

Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients USA - English Israel - English

Oct 4, 2021

NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2021

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 1, 2021

T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Oct 1, 2021

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer's 2021 Annual Meeting

Oct 1, 2021

Aleta Biotherapeutics to Present at Society for Immunotherapy of Cancer

Sep 30, 2021

Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 30, 2021

Gennao Bio Announces Abstract Accepted for Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 30, 2021

OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy

Sep 30, 2021

BridGene Biosciences Announces Titles and Authors of Five Abstracts Accepted for Poster Presentations at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Sep 30, 2021

CatalYm To Present Update From GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Sep 30, 2021

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Sep 28, 2021

Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy

Sep 28, 2021

Immunicom’s Alternative Subtractive Cancer Therapy Recognized with Zoom’s Healthcare Innovation Award

Sep 28, 2021

Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Sep 26, 2021

JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

Sep 22, 2021

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Sep 22, 2021

Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

Sep 22, 2021

CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications

Sep 22, 2021

OncoNano Medicine Announces Expanded Research Collaboration With UT Southwestern Medical Center to Advance Development of New Cancer Therapies

Sep 21, 2021

Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer

Sep 21, 2021

LIPAC Oncology to Present at Upcoming Investor Conferences

Sep 21, 2021

Immunicom Introduces 2nd Product of Immunopheresis Therapy Platform Designed to Suppress Cancer Progression and Overcome Therapeutic Resistance

Sep 21, 2021

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

Sep 21, 2021

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study

Sep 21, 2021

Seneca Therapeutics, Inc. Announces Launch of a Novel Cancer Gene Delivery Platform based on SVV-001 Technology

Sep 21, 2021

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0682 in ER-Positive Breast Cancer

Sep 21, 2021

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

Sep 20, 2021

Fore Biotherapeutics Continues to Build Leadership Team with Executive and Board Appointments

Sep 19, 2021

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

Sep 17, 2021

Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)

Sep 16, 2021

BERG to Present Latest Research to Improve Pancreatic Treatment at The European Society for Medical Oncology (ESMO) 2021 Congress

Sep 16, 2021

Nouscom announces initial results from Phase 1 trial for NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine, in MSI-H solid tumors

Sep 16, 2021

Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021

Sep 16, 2021

OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021

Sep 16, 2021

Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress

Sep 16, 2021

Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program from Salk Institute and Sanford Burnham Prebys to Broaden Its Precision Oncology Pipeline

Sep 16, 2021

Shasqi Presents Initial Data Validating Approach of Click Chemistry Activated Oncology Therapeutics at ESMO Congress 2021

Sep 14, 2021

Pyxis Oncology Appoints Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer

Sep 14, 2021

Immunicom Presents Promising Preliminary Data from Immunopheresis Studies in Late-Stage Cancer Patients at JCA-AACR 2021

Sep 14, 2021

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

Sep 13, 2021

Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021

Sep 13, 2021

ITM and Chengdu Gaotong Isotope Co. Ltd. Form Joint Venture to Expand Access to ITM’s Diagnostic and Therapeutic Radioisotopes in China

Sep 9, 2021

USPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

Sep 9, 2021

Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology

Sep 9, 2021

CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO (nivolumab) in Metastatic Urothelial Cancer

Sep 9, 2021

PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer

Sep 8, 2021

Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes

Sep 8, 2021

Pyxis Oncology Strengthens Board of Directors

Sep 7, 2021

Istari Oncology to Participate in Upcoming Virtual Investor Conferences

Sep 7, 2021

Systems Oncology to Present at Upcoming Scientific and Investor Conferences

Sep 2, 2021

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers USA - English USA - English

Sep 2, 2021

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers

Sep 1, 2021

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

Sep 1, 2021

Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal Cancer

Aug 31, 2021

Pyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer

Aug 31, 2021

Immunicom Hires World-Renowned Oncologist to Rapidly Progress Launch of Non-Pharmaceutical Cancer Therapy

Aug 30, 2021

Umoja Biopharma Breaks Ground on Extensive Manufacturing Facility for its Next-Generation CAR T Immunotherapies

Aug 26, 2021

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

Aug 26, 2021

Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer

Aug 25, 2021

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

Aug 25, 2021

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

Aug 25, 2021

Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613 (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Aug 24, 2021

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

Aug 24, 2021

Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer

Aug 20, 2021

Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention and Research Institute of Texas

Aug 18, 2021

Treos Bio Announces FDA Clearance of IND Application for PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

Aug 18, 2021

Ranok Therapeutics Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline

Aug 17, 2021

Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021

Aug 17, 2021

Istari Oncology Initiates Its Phase I/II Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer

Aug 17, 2021

Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients

Aug 16, 2021

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

Aug 16, 2021

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

Aug 16, 2021

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2ꟷ Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

Aug 16, 2021

Immunicom Continues Successful Immunopheresis Clinical Trial in Advanced, Non-Small Cell Lung Cancer Treatment with Acibadem University

Aug 16, 2021

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2- Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

Aug 16, 2021

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

Aug 15, 2021

InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer

Aug 11, 2021

BridGene Biosciences Announces Acceptance of Five Abstracts for Poster Presentations at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Aug 10, 2021

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy

Aug 10, 2021

Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies

Aug 5, 2021

Versant Ventures Announces Acquisition of Portfolio Company Vividion Therapeutics

Aug 4, 2021

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

Aug 4, 2021

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

Aug 3, 2021

Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 -- a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions -- in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy USA - English USA - English USA - English

Aug 3, 2021

Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

Aug 2, 2021

Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer

Aug 2, 2021

DSS Continues to Grow its Healthcare Segment through $1M Investment in Vivacitas Oncology

Jul 29, 2021

Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology

Jul 29, 2021

BERG Reveals New Study That Will Seek to Enhance Diagnosis and Treatment of Prostate Cancer

Jul 28, 2021

Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers

Jul 27, 2021

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

Jul 22, 2021

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Jul 21, 2021

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS T Cell Therapy in Liver Cancer

Jul 21, 2021

Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture

Jul 20, 2021

CureLab Oncology Granted US Patent for Therapeutic Use of its Lead Product in ALS, Alzheimer's, Huntington's, and Parkinson's Diseases

Jul 20, 2021

Immunicom’s Data at ASCO Expand on the Antitumor Activity of its Novel Non-Pharmaceutical Immunotherapy in Late-Stage Breast Cancer Patients

Jul 19, 2021

Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha

Jul 19, 2021

Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline

Jul 14, 2021

Iterion Therapeutics Hires Jean Chang as Chief Operating Officer

Jul 14, 2021

GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

Jul 12, 2021

Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma

Jul 7, 2021

Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor

Jul 6, 2021

Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement

Jul 2, 2021

Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer

Jun 30, 2021

Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer

Jun 30, 2021

ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Jun 29, 2021

Applied BioMath, LLC Announces Collaboration with Ichnos Sciences for Systems Pharmacology Modeling for a Bispecific Antibody in Oncology

Jun 29, 2021

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 (Devimistat) for Treatment of Biliary Cancer

Jun 29, 2021

IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial

Jun 29, 2021

Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology

Jun 25, 2021

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

Jun 24, 2021

Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology

Jun 24, 2021

Elevation Oncology Announces Pricing of Initial Public Offering

Jun 24, 2021

Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target

Jun 24, 2021

Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer

Jun 24, 2021

Kineta's Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA: A New Immunotherapy Approach to Treating Cancer

Jun 24, 2021

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer

Jun 23, 2021

Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic

Jun 23, 2021

Immunicom Presentation Defines Breakthrough Subtractive Therapy’s Role in “New Era” Cancer Care at LSI’s Annual Emerging MedTech Summit

Jun 23, 2021

Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer

Jun 22, 2021

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

Jun 22, 2021

TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases

Jun 21, 2021

Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company

Jun 20, 2021

Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Receives Approval for Clinical Trial in France

Jun 17, 2021

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board

Jun 17, 2021

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer

Jun 17, 2021

Elevation Oncology Announces Appointment of Joseph Ferra as Chief Financial Officer

Jun 17, 2021

PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer

Jun 16, 2021

Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer

Jun 15, 2021

Caris Life Sciences and Elevation Oncology Announce Joint Discovery and Development Collaboration Focused on Oncogenic Fusions and Driver Mutations

Jun 15, 2021

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

Jun 15, 2021

OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of Florida

Jun 15, 2021

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer

Jun 14, 2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

Jun 14, 2021

Asher Bio Appoints Leading Experts in Immunology, Oncology and Protein Therapeutics to its Scientific Advisory Board

Jun 10, 2021

Immunicom Presents Promising Clinical Trial Data at AACR in Late-Stage Breast Cancer Patients Treated with Novel Non-Pharmaceutical Immunotherapy

Jun 10, 2021

ITM Announces EUR 25 Million (USD 30 M) Private Equity Financing to Support Advancement of Proprietary Precision Oncology Pipeline

Jun 9, 2021

LIPAC Oncology Announces Two-Year Recurrence Free Survival Data for Phase 1/2a Study of LiPax in Patients With Non-Muscle Invasive Bladder Cancer

Jun 8, 2021

ONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project to Optimize Metabolism of NK Cells for Improved Cancer Therapies

Jun 8, 2021

Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR Cancer

Jun 8, 2021

Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team

Jun 8, 2021

Pyxis Oncology Strengthens Leadership Team with Executive and Scientific Advisory Board Appointments

Jun 7, 2021

NeoImmuneTech Trial Data Presented at American Society of Clinical Oncology Annual Meeting

Jun 4, 2021

Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 4, 2021

Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 4, 2021

Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors

Jun 3, 2021

Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program

Jun 2, 2021

BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Patients at 2021 American Society of Clinical Oncology (ASCO) Meeting

Jun 2, 2021

Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors

Jun 2, 2021

Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate

Jun 2, 2021

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

Jun 1, 2021

Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Jun 1, 2021

Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer

May 30, 2021

Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

May 27, 2021

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies

May 27, 2021

enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial

May 27, 2021

Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models

May 26, 2021

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613 (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

May 26, 2021

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers USA - English USA - English

May 26, 2021

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers

May 26, 2021

CancerVAX Announces Research Program to Develop Its First Immunotherapy Cancer Treatment

May 25, 2021

Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases

May 25, 2021

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer

May 20, 2021

Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2021

NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting

May 20, 2021

BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology

May 20, 2021

Istari Oncology Honored as “Best Early Stage Product Development Company” in the Triangle Business Journal’s Life Sciences Awards

May 20, 2021

Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting

May 20, 2021

IN8bio Presents First Cohort Phase 1 Clinical Data on INB-200 at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

May 20, 2021

Novo Holdings co-leads oversubscribed CHF 100 Million (USD 110 M) Series C in Numab Therapeutics

May 19, 2021

Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody, Sotigalimab (APX005M), in Combination Therapy for Metastatic Pancreatic Cancer at the ASCO 2021 Annual Meeting

May 19, 2021

Bicara Therapeutics to Present Clinical Data from Lead Immunotherapy Program, BCA101, at the American Society of Clinical Oncology 2021 Annual Meeting

May 19, 2021

Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment

May 18, 2021

Elevation Oncology Appoints Michael Carruthers to Board of Directors and Chair of the Audit Committee

May 18, 2021

Novo Holdings leads US$125 Million Series C in Hummingbird Bioscience

May 18, 2021

Elevar Therapeutics Announce New Data Highlighting Patient Burden and Unmet Needs Associated with Cremophor-Based Cancer Treatments

May 17, 2021

Genenta Appoints Four Renowned Oncology Experts to Scientific Advisory Board

May 17, 2021

Boundless Bio Announces Educational Session on Extrachromosomal DNA (ecDNA) at the American Association for Cancer Research (AACR) Annual Meeting 2021

May 17, 2021

Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer

May 17, 2021

AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

May 13, 2021

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021

May 13, 2021

LIPAC Oncology Names Daniel K. Spiegelman as Independent Board Advisor

May 13, 2021

Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors

May 13, 2021

Interline Therapeutics Launches With $92 Million to Map and Correct Dysfunctional Protein Communities

May 13, 2021

Systems Oncology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference

May 13, 2021

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform USA - English Deutschland - Deutsch España - español France - Français

May 12, 2021

Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium

May 12, 2021

Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis

May 11, 2021

FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer

May 6, 2021

Penrose TherapeuTx Expands Scientific Advisory Board with Three World-Renowned Oncology Researchers

May 6, 2021

Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting Reflect Continued Progress in the Clinical Development of PVSRIPO

May 6, 2021

Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis

May 6, 2021

Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research

May 6, 2021

LIPAC Oncology Announces Appointment of Josh Hamermesh to the Board of Directors

May 6, 2021

ITM Establishes Subsidiary in Shanghai to Accelerate Introduction of Its Precision Oncology Portfolio in China

May 5, 2021

SEngine Precision Medicine’s PARIS Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR’s Molecular Cancer Therapeutics

May 5, 2021

BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company's Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs

May 4, 2021

Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target

May 4, 2021

Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors

May 3, 2021

Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer

May 3, 2021

Lantern Pharma and Actuate Therapeutics Announce Research and Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

Apr 30, 2021

Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference

Apr 29, 2021

SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting

Apr 29, 2021

Istari Oncology Hires Marc Banjak as General Counsel and Secretary as the Company Prepares for a Critical Period of Development and Expansion

Apr 29, 2021

LIPAC Oncology Announces Successful Type B Meeting with the U.S. FDA for the Study of LiPax for Non-Muscle Invasive Bladder Cancer

Apr 29, 2021

Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 29, 2021

Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board

Apr 29, 2021

Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting

Apr 29, 2021

Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

Apr 29, 2021

Novo Seeds co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

Apr 28, 2021

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)

Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery USA - English USA - English

Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery

Apr 27, 2021

Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential

Apr 27, 2021

Shasqi Awarded Prestigious Direct-to-Phase-2 Small Business Innovation Research Grant by National Cancer Institute

Apr 26, 2021

Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor USA - English USA - English

Apr 26, 2021

Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

Apr 25, 2021

Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer

Apr 22, 2021

ITM Raises EUR 90 M (USD 109 M) to Accelerate Precision Oncology Pipeline and Support Ongoing Phase 3 Clinical Program

Apr 22, 2021

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

Apr 21, 2021

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma

Apr 21, 2021

BioCurity Pharmaceuticals Inc. Files a US Provisional Patent Application Drawn to Pharmaceutical Formulations of Cerium Oxide Nanoparticles Designed to Prevent Radiation Therapy Side Effects for Cancer Patients Undergoing Radiation Therapy

Apr 21, 2021

Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer

Apr 20, 2021

IconOVir Bio Announces Formation of Scientific Advisory Board

Apr 20, 2021

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Apr 20, 2021

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

Apr 19, 2021

Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors

Apr 19, 2021

Pyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug Conjugates

Apr 18, 2021

Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer

Apr 16, 2021

AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020

Apr 15, 2021

Alchemab to Collaborate With AstraZeneca to Use Alchemab’s Drug Discovery Platform for Prostate Cancer Study

Apr 14, 2021

Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies

Apr 14, 2021

Aura Biosciences Announces Publication of Data in Cancer Immunology Research, Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment

Apr 14, 2021

BERG Announces Oncology Pipeline Advancements And Biomarker Developments For Clinical Decision Support In Breast Cancer At AACR

Apr 14, 2021

StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells

Apr 14, 2021

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug

Apr 13, 2021

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

Apr 13, 2021

SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer

Apr 13, 2021

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors

Apr 12, 2021

Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Apr 12, 2021

Seneca Therapeutics Reports Late Breaking Information on SVV-001 from the American Association for Cancer Research’s 2021 Annual Meeting

Apr 12, 2021

Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety

Apr 10, 2021

Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling

Apr 10, 2021

Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for Cancer Research (AACR)

Apr 10, 2021

Boundless Bio Presents Data on the Role of Extrachromosomal DNA (ecDNA) in Mediating Resistance to Targeted Therapies at the American Association for Cancer Research (AACR) Annual Meeting 2021

Apr 9, 2021

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting

Apr 9, 2021

MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment

Apr 9, 2021

Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

Apr 9, 2021

Systems Oncology to Present at BMO BioPharma Spotlight Series

Apr 8, 2021

Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021

Apr 8, 2021

DSS Expands its Healthcare Segment through Investment in Vivacitas Oncology

Apr 8, 2021

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program

Apr 7, 2021

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

Apr 6, 2021

Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models

Apr 6, 2021

MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer

Apr 6, 2021

Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy USA - English USA - English

Apr 6, 2021

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021

Apr 5, 2021

Teon Therapeutics to Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference

Apr 1, 2021

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy USA - English USA - English

Apr 1, 2021

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

Mar 31, 2021

Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma

Mar 31, 2021

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 31, 2021

OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing

Mar 31, 2021

Myeloid Therapeutics Appoints Elaine Jones, Ph.D., to its Board of Directors

Mar 31, 2021

Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics

Mar 30, 2021

Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics

Mar 30, 2021

Applied BioMath, LLC Announces Collaboration with Asher Biotherapeutics for Systems Pharmacology Modeling in Oncology

Mar 29, 2021

Cytocom to Present at the Spring 2021 Virtual Oncology Investor Conference

Mar 29, 2021

CORRECTING and REPLACING Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma

Mar 26, 2021

Oncology Investors to Hear “Cancer Device Company of the Year” Immunicom Present at MedInvest Conference

Mar 25, 2021

Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional T Cells—Critical for Antitumor Immunity

Mar 24, 2021

Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer

Mar 23, 2021

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Mar 23, 2021

GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

Mar 23, 2021

Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform

Mar 22, 2021

Aura Biosciences Announces Oversubscribed $80 Million Financing

Mar 22, 2021

LDC and Cumulus Oncology announce collaboration

Mar 19, 2021

Cygnal Therapeutics to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 18, 2021

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

Mar 18, 2021

Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs

Mar 18, 2021

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

Mar 17, 2021

Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer

Mar 16, 2021

Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

Mar 15, 2021

ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors

Mar 15, 2021

VLP Therapeutics raises $16M Series A for cancer treatment vaccine RandD

Mar 15, 2021

Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy

Mar 15, 2021

Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021

Mar 11, 2021

ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021

Mar 11, 2021

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

Mar 10, 2021

LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting

Mar 10, 2021

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech

Mar 10, 2021

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 10, 2021

Prominent Mitochondrial Researcher Dr. Navdeep Chandel Joins Penrose TherapeuTx Scientific Advisory Board

Mar 10, 2021

SEngine Precision Medicine to Present Data on Predictive Value of PARIS Test in Ovarian Cancer Patients at 2021 AACR Annual Conference

Mar 9, 2021

MD Anderson’s Therapeutics Discovery Division, Orionis Biosciences Launch Project Helios to Advance Novel Small-Molecule Cancer Medicines

Mar 9, 2021

Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment

Mar 8, 2021

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer

Mar 4, 2021

DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis

Mar 4, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

Mar 4, 2021

Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline

Mar 3, 2021

Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology

Mar 3, 2021

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs

Mar 2, 2021

Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer

Mar 2, 2021

ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference

Mar 2, 2021

Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study

Mar 1, 2021

CytoImmune Therapeutics Establishes Operations in Puerto Rico to Develop Novel Cancer Immunotherapy Products

Feb 24, 2021

Cybrexa Therapeutics Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop CBX-12 (alphalex™- exatecan)

Feb 22, 2021

NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States and Appoints Dieter Weinand as Chairman of the Board and Usama Malik as Chief Executive Officer and Director of the Board

Feb 17, 2021

Edison Oncology to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Feb 16, 2021

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

Feb 16, 2021

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings

Feb 11, 2021

DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors (AT/RT and CNS-PNET) Published in Clinical Cancer Research

Feb 11, 2021

Penrose TherapeuTx Appoints Oncology Clinical Development Veteran Bhardwaj Desai, M.D. as Chief Development Officer

Feb 10, 2021

Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company

Feb 10, 2021

Shasqi Announces Strategic Advisors as it Advances Click-Chemistry Based Treatments for Cancer

Feb 10, 2021

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies

Feb 9, 2021

Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy

Feb 5, 2021

Global Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Insights Report 2020 Featuring Takeda Oncology, Epizyme, Vyriad, Novartis, DNAtrix, Pfizer, Oncoceutics and Istari Oncology - ResearchAndMarkets.com

Feb 2, 2021

MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo (cemiplimab) in Advanced Non-Small Cell Lung Cancer

Feb 1, 2021

Advanced Pancreatic Cancer Pipeline Therapeutics and Analysis, 2021

Jan 28, 2021

ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer

Jan 26, 2021

OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 / OST31-164-01 An Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma

Jan 25, 2021

Immunicom Makes StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”

Jan 21, 2021

CureLab Oncology Launches Veterinary Oncology Subsidiary, CureLab Veterinary

Jan 21, 2021

Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology

Jan 19, 2021

Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference

Jan 19, 2021

Second Genome To Present Biomarker Data in Oncology at Keystone Symposium

Jan 19, 2021

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Jan 18, 2021

Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients

Jan 14, 2021

Adastra Pharmaceuticals, Inc. to Present at Inaugural B. Riley Securities' Oncology Investor Conference

Jan 13, 2021

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

Jan 13, 2021

Novo Seeds' Portfolio Company, IO Biotech, Completes Oversubscribed EUR 127M Series B Financing to Accelerate Clinical Programs in Oncology

Jan 13, 2021

Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas

Jan 13, 2021

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

Jan 13, 2021

HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization

Jan 13, 2021

Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors

Jan 12, 2021

Elucida Oncology Closes $44 Million Series A-1 Financing

Jan 12, 2021

Global $3.9 Bn Microbiome Therapeutics Markets to 2030: Market Opportunities with the Growing Eminence of Microbiome Therapeutics in Cancer Treatment

Jan 12, 2021

DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy

Jan 11, 2021

Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

Jan 11, 2021

Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma

Jan 11, 2021

Rakuten Medical, Inc. Acquires Key Assets and Manufacturing Technology from LI-COR Biosciences

Jan 11, 2021

EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T Program

Jan 8, 2021

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

Jan 8, 2021

Cellares Adds PACT Pharma to its Early Access Partnership Program USA - English España - español Deutschland - Deutsch France - Français

Jan 8, 2021

ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer USA - English USA - English USA - English España - español España - español Deutschland - Deutsch Deutschland - Deutsch France - Français France - Français

Jan 8, 2021

ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer USA - English Israel - English USA - español USA - Deutsch USA - Français

Jan 8, 2021

ATP et Biolojic Design lancent Aulos Bioscience pour développer une approche hautement différenciée des anticorps IL-2 dans la lutte contre le cancer USA - Français USA - English Israel - English USA - español USA - Deutsch

Jan 7, 2021

Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic

Jan 7, 2021

Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference

Jan 7, 2021

BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease

Jan 7, 2021

Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing

Jan 7, 2021

ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors

Jan 6, 2021

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials

Jan 6, 2021

Elevation Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference

Dec 30, 2020

ImmunityBio Appoints Fabio M. Benedetti, M.D., as Chief Strategy Officer

Dec 23, 2020

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

Dec 21, 2020

Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer

Dec 21, 2020

ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate

Dec 20, 2020

Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer

Dec 17, 2020

Cullinan Oncology Completes $131.2 Million Series C Financing

Dec 14, 2020

Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK

Dec 14, 2020

ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Dec 10, 2020

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

Dec 10, 2020

Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics

Dec 10, 2020

Silicon Therapeutics Announces Members of Scientific Advisory Board

Dec 10, 2020

LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons Co., Ltd.

Dec 10, 2020

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Dec 10, 2020

CG Oncology Closes $47 Million Series D Financing

Dec 9, 2020

North America Cancer Vaccines Market Report 2020-2027 Featuring Leading Players - AstraZeneca, GSK, Aduro Biotech, Pfizer, Sanofi, Bristol-Myers Squibb, Moderna, OncBioMune, MaxiVAX, Nouscom

Dec 9, 2020

Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting

Dec 9, 2020

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

Dec 9, 2020

SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium

Dec 9, 2020

CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA (pembrolizumab) for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Dec 9, 2020

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

Dec 9, 2020

Boehringer Ingelheim to Acquire Labor Dr. Merk and Kollegen to Strengthen its Next Generation Cancer Immunology Program

Dec 8, 2020

RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer

Dec 8, 2020

Candel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments

Dec 7, 2020

Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt Biotherapeutics' Boltbody™ ISAC Platform

Dec 7, 2020

ALX Oncology Announces Proposed Public Offering of Common Stock

Dec 7, 2020

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies

Dec 7, 2020

ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

Dec 7, 2020

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

Dec 3, 2020

enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer

Dec 3, 2020

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

Dec 3, 2020

Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020

Dec 3, 2020

Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer

Dec 3, 2020

IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product candidate, at ASH 2020

Dec 3, 2020

IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021

Dec 2, 2020

Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020

Dec 2, 2020

Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

Dec 2, 2020

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

Dec 2, 2020

AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

Dec 1, 2020

Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology

Dec 1, 2020

LianBio Announces Clearance to Initiate in China the Phase 2a Trial of Infigratinib in Patients with Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma with FGFR2 Gene Amplification

Dec 1, 2020

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

Dec 1, 2020

Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer

Nov 30, 2020

Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma

Nov 24, 2020

Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2

Nov 24, 2020

SEngine Precision Medicine to Present Data from Predictive Value of PARIS Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium

Nov 23, 2020

ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing

Nov 23, 2020

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

Nov 23, 2020

Penrose TherapeuTx Appoints Business Leader Mark de Souza as Chief Executive Officer to Help Drive New Innovations in Oncology

Nov 20, 2020

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange

Nov 19, 2020

Elevar Therapeutics Presents Safety and Efficacy Results of Rivoceranib (apatinib) in Combination with Nivolumab at the 2020 Connective Tissue Oncology Society (CTOS) Annual Meeting

Nov 18, 2020

Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer

Nov 18, 2020

AUM Biosciences and Newsoara Biopharma Announce a 5-year Transformational Strategic Partnership to Co-develop and Co-discover Next-generation Cancer Therapeutics

Nov 17, 2020

AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

Nov 16, 2020

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer

Nov 16, 2020

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer

Nov 16, 2020

Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Nov 12, 2020

Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology English Français Deutsch

Nov 12, 2020

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Nov 12, 2020

CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO (nivolumab) in Muscle-Invasive Bladder Cancer

Nov 12, 2020

Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology USA - English USA - Français USA - Deutsch

Nov 11, 2020

Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute

Nov 10, 2020

Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

Nov 10, 2020

Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA (pembrolizumab) in patients with Triple-negative Breast Cancer

Nov 10, 2020

Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2020

Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613 (devimistat) for the Treatment of Pancreatic Cancer

Nov 10, 2020

Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer

Nov 9, 2020

Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020

Nov 9, 2020

Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPα Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

Nov 9, 2020

Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPalpha Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 9, 2020

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Nov 9, 2020

Cygnal Therapeutics to Present Poster at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Nov 5, 2020

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

Nov 4, 2020

NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac for Intratumoral Treatment of Prostate Cancer

Nov 2, 2020

AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy

Nov 2, 2020

enGene Announces FDA Clearance of IND Application for EG-70, an intravesical dual-immune modulator for the treatment of non-muscle invasive bladder cancer

Oct 29, 2020

Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer

Oct 29, 2020

AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer USA - English USA - English

Oct 29, 2020

Worldwide Dendritic Cell Cancer Vaccine Immunotherapy Industry to 2026 - Featuring 3M, Activartis and Argos Therapeutics Among Others

Oct 29, 2020

AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer

Oct 27, 2020

Syntrix Completes Initial SX-682 Dosing in Broad Phase 1/2 Cancer Trial Campaign Now Encompassing 5 Solid Cancer Types Plus Myelodysplastic Syndromes

Oct 27, 2020

Prokarium Closes $21M Series B Financing Round and Strengthens Board

Oct 26, 2020

Arch Oncology to Present at Upcoming Conferences

Oct 26, 2020

Boundless Bio Presents Research Showcasing its Imaging and Single-Cell Sequencing Platform for Extrachromosomal DNA (ecDNA) Detection at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting

Oct 26, 2020

Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling

Oct 26, 2020

Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0

Oct 22, 2020

Phosplatin Therapeutics Doses First Patient in Phase 2 Study of PT-112 in Metastatic Castration Resistant Prostate Cancer Patients

Oct 22, 2020

Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer

Oct 21, 2020

Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development

Oct 21, 2020

NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer

Oct 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region USA - English USA - English USA - English

Oct 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region USA - English Middle East - English

Oct 20, 2020

WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Oct 20, 2020

Immunomic Therapeutics’ CEO to Present at the 5th International Virtual Conference on Cancer Research and Development 2020

Oct 20, 2020

A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613️ (devimistat) for Patients With Pancreatic Cancer in Japan

Oct 20, 2020

SEngine Precision Medicine’s PARIS Test Identifies Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine

Oct 20, 2020

Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy

Oct 18, 2020

Prestige Biopharma Receives Positive EMA Opinion on Orphan Designation for PBP1510 for Treatment of Pancreatic Cancer

Oct 15, 2020

Apexigen's APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

Oct 14, 2020

Totient Leverages Integral Molecular's Membrane Proteome Array to Advance Cancer Therapeutic Discovery

Oct 14, 2020

ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

Oct 14, 2020

RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics

Oct 14, 2020

CureLab Oncology Appoints The Honorable David J. Shulkin, M.D. to its Scientific Advisory Board

Oct 13, 2020

Nuvation Bio Announces FDA Acceptance of Investigational New Drug (IND) Application for NUV-422 for Treatment of Patients with High-grade Gliomas

Oct 13, 2020

WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow Infiltrating Lymphocytes (MILs)

Oct 13, 2020

CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment

Oct 13, 2020

Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib

Oct 13, 2020

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Oct 13, 2020

Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Cancer

Oct 12, 2020

Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

Oct 8, 2020

Philogen Announces Publication of Malignant Brain Tumor Study Results in Science Translational Medicine

Oct 6, 2020

NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care

Oct 5, 2020

Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors

Oct 5, 2020

Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

Oct 1, 2020

Elucida Oncology Appoints Dr. Eliel Bayever as Chief Medical Officer

Sep 30, 2020

Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada

Sep 30, 2020

Elevation Oncology and US Oncology Research Announce Collaboration to Expand Genomic Testing of Solid Tumors and Local Site Activation in Support of the Phase 2 CRESTONE Study

Sep 30, 2020

Verastem Oncology Announces Closing of COPIKTRA (duvelisib) Sale to Secura Bio

Sep 30, 2020

Secura Bio Completes Acquisition of Global Rights to Oncology Drug Copiktra

Sep 29, 2020

Neuropore Therapies Licenses Autophagy Modulators to Global Cancer Technology for Treatment of Cancers and Other Life-Threatening Diseases

Sep 25, 2020

Decipher Biosciences Achieves Major Medicare Milestone with Expansion in Coverage for Decipher Prostate Genomic Testing

Sep 25, 2020

Accent Therapeutics Appoints Oncology Drug Development Veteran Julie Hambleton to its Board of Directors

Sep 25, 2020

Rakuten Medical Japan Announces Marketing Approval of Akalux IV Infusion 250mg and BioBlade Laser System from the Ministry of Health, Labour and Welfare in Japan for Locoregional Cancer Treatment

Sep 24, 2020

KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 24, 2020

Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform

Sep 23, 2020

Systems Oncology, an AI-based Cancer Therapy Discovery and Development Company, Is Honored With a 2020 AZBio Fast Lane Award

Sep 23, 2020

Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform

Sep 22, 2020

Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myelodysplastic Syndromes/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

Sep 22, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer

Sep 18, 2020

BERG To Present Discovery/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinoma (PDAC) Treated With BPM 31510-IV At The European Society For Medical Oncology (ESMO) 2020 Congress

Sep 18, 2020

Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301 in Combination with Pembrolizumab in Advanced Head and Neck Cancer Patients at ESMO 2020

Sep 18, 2020

Rafael Pharmaceuticals to Present Pancreatic and Biliary Tract Cancer Data on CPI-613 (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress

Sep 17, 2020

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases

Sep 17, 2020

Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

Sep 16, 2020

Ashion Analytics announces innovative cancer treatment partnership with Elevation Oncology

Sep 16, 2020

OCTIMET partners OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China

Sep 15, 2020

Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML

Sep 15, 2020

Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy

Sep 15, 2020

Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™

Sep 15, 2020

Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies

Sep 14, 2020

LAVA Therapeutics, Amsterdam UMC and Monash University Announce Publication of a Novel Cancer Immunotherapy Approach in Nature Cancer

Sep 14, 2020

NASIR-HCC: Phase 2 study of Sirtex Medical SIR-Spheres Y-90 resin microspheres followed by Nivolumab therapy demonstrates favorable safety and tolerability profile at ILCA 2020

Sep 11, 2020

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

Sep 11, 2020

Cancer Prevention Pharmaceuticals Announces NEJM Publication of Landmark Phase 3 Clinical Trial for Treatment of Familial Adenomatous Polyposis

Sep 10, 2020

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

Sep 9, 2020

MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer English English

Sep 9, 2020

OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics

Sep 9, 2020

Enterome - First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative 'OncoMimic' based Immunotherapy Candidate Targeting Adrenal Tumors

Sep 9, 2020

MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer USA - English USA - English USA - English USA - English USA - English USA - English USA - English USA - English España - español España - español

Sep 8, 2020

LIPAC Oncology Announces Completion of Phase 2A Clinical Trial of LiPax in Patients with Non-Muscle Invasive Bladder Cancer

Sep 7, 2020

AnHeart Licenses Two Clinical Stage Oncology Candidates from Daiichi Sankyo

Sep 7, 2020

Cycle Pharmaceuticals Secures $25 Million Debt Financing

Sep 2, 2020

Highlight Therapeutics Announces Second Phase II Oncology Collaboration with Merck

Aug 27, 2020

Treadwell Announces Initiation of Expansion Cohorts in Ongoing Phase 1 Study of Oral TTK Inhibitor, CFI-402257, in Patients with Breast Cancer and Additional Solid Tumors

Aug 26, 2020

RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer

Aug 25, 2020

Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer

Aug 24, 2020

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

Aug 24, 2020

Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models

Aug 24, 2020

PEEL Therapeutics Developing Cancer Drug from Plant Toxin

Aug 19, 2020

Apexigen Appoints Jakob Dupont to Board of Directors

Aug 18, 2020

Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer

Aug 17, 2020

Boundless Bio Announces Publication in Nature Genetics Detailing the Association Between Extrachromosomal DNA-Based Oncogene Amplification and Poor Cancer Outcomes

Aug 17, 2020

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

Aug 17, 2020

Tango Therapeutics Announces $50 Million Equity Financing

Aug 12, 2020

Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC): IND.239

Aug 11, 2020

Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform

Aug 11, 2020

Caris Life Sciences Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions

Aug 10, 2020

Secura Bio Signs Agreement to Acquire Global Rights to Oncology Drug Copiktra

Aug 9, 2020

AnHeart Announces Entry into Series A+ Equity Financing Agreements

Aug 6, 2020

Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Aug 4, 2020

Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4

Aug 4, 2020

POINT Biopharma Announces Successful USD $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients

Aug 4, 2020

Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors

Aug 3, 2020

Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.

Jul 30, 2020

Enterome initiates first clinical trial with EO2401 - an innovative microbiome-antigen ('OncoMimic') based cancer immunotherapy candidate targeting aggressive brain cancer

Jul 29, 2020

Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish English English Français Deutsch España - español Italia - Italiano

Jul 29, 2020

Akoya Biosciences Collaborates with Leading Cancer Center to Discover Predictive Biomarkers for Cancer

Jul 29, 2020

Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs

Jul 28, 2020

Innovative Cellular Therapeutics to Present New Clinical Data with CoupledCAR CAR-T in Colon Cancer at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020

Jul 28, 2020

Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors

Jul 28, 2020

American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure Research

Jul 28, 2020

Propanc Biopharma Receives Investment from Institutional Investor

Jul 22, 2020

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

Jul 22, 2020

Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy

Jul 21, 2020

Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets English Deutsch Français español

Jul 21, 2020

First Patient Dosed with Taletrectinib in AnHeart Phase 2 Trial of Non-Small Cell Lung Cancer with ROS1 Fusion

Jul 21, 2020

SEngine Precision Medicine’s PARIS Test to Guide Personalized Treatment Demonstrates Clinical Utility in Metastatic Colorectal Cancer Study Published in AACR’s Clinical Cancer Research

Jul 21, 2020

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations

Jul 21, 2020

Strata Oncology Partners with Elevation Oncology to Accelerate Enrollment of CRESTONE Study for Patients with Rare NRG1 Gene Fusions

Jul 21, 2020

Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets USA - English USA - Deutsch USA - Français USA - español

Jul 16, 2020

ALX Oncology Announces Pricing of Initial Public Offering

Jul 14, 2020

iOnctura Extends Series A to EUR 20.1M

Jul 9, 2020

Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics

Jul 9, 2020

Kronos Bio Reports Positive Results of Preclinical Study of KB-0742, an Investigational CDK9 Inhibitor, Demonstrating Potency, Selectivity and Anti-tumor Activity in Prostate Cancer Model

Jul 9, 2020

Unconventional Weapon in the War on Cancer Revealed: Immunicom and Sheba Medical Center Initiate Clinical Trial to Evaluate Breakthrough Oncology Treatment, Immunopheresis Therapy

Jul 8, 2020

Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer

Jul 8, 2020

Lava Therapeutics Appoints Oncology and Hematology Expert Benjamin Winograd, M.D., Ph.D., as Chief Medical Officer

Jul 7, 2020

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Jul 7, 2020

MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO

Jul 2, 2020

AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Research

Jun 29, 2020

Cancer Prevention Pharmaceuticals Submits New Drug Application to the FDA for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

Jun 29, 2020

Rakuten Medical Receives Conditional Early Approval Designation from Japanese Health Ministry for its Lead Drug, ASP-1929, to Treat Recurrent Head and Neck Cancer

Jun 26, 2020

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer English English

Jun 26, 2020

AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research

Jun 26, 2020

Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer

Jun 23, 2020

Vitanova Biomedical and LiteCure Medical Lasers Announce Global Strategic Partnership

Jun 23, 2020

ITM and POINT Biopharma Sign Two Supply Agreements for No-carrier-added Lutetium-177

Jun 23, 2020

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer

Jun 22, 2020

twoXAR Pharmaceuticals Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311

Jun 22, 2020

Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II

Jun 22, 2020

Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II

Jun 22, 2020

Arch Oncology Announces Formation of Scientific Advisory Board

Jun 22, 2020

SEngine Precision Medicine Presents Innovative Data on the CLIA Certified PARIS Test for Oncology Drug Sensitivity and the Future of Functional Precision Medicine at AACR 2020

Jun 22, 2020

Rakuten Medical Presents Data during AACR Characterizing how Illuminox (an Investigational Platform based on Photoimmunotherapy) Induces Cancer Cell Death and Enhances the Immune Response Preclinically

Jun 22, 2020

Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model

Jun 18, 2020

Cancer Prevention Pharmaceuticals Submits EU Marketing Authorization Application for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

Jun 18, 2020

CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020

Jun 16, 2020

eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept

Jun 16, 2020

Boundless Bio Scientific Co-Founder Paul Mischel to Present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

Jun 16, 2020

Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform

Jun 15, 2020

Medison Pharma and Alpha Tau Medical Announce a Collaboration in the Oncology Field in Central and Eastern Europe English English English

Jun 15, 2020

Medison Pharma and Alpha Tau Medical Announce a Collaboration in the Oncology Field in Central and Eastern Europe USA - English Israel - English

Jun 12, 2020

ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Jun 11, 2020

Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing

Jun 11, 2020

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology

Jun 10, 2020

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

Jun 10, 2020

DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline

Jun 10, 2020

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology

Jun 9, 2020

NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac in Lung Cancer

Jun 9, 2020

Azitra Relocates to Accommodate Sustained Growth

Jun 9, 2020

Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001

Jun 8, 2020

Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study

Jun 4, 2020

Cullinan Oncology Completes $98.5 Million Series B Financing

Jun 4, 2020

Accent Therapeutics and AstraZeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration

Jun 4, 2020

Rakuten Medical and MD Anderson Announce Strategic Alliance to Advance Illuminox Platform for Cancer Treatments

Jun 3, 2020

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

Jun 1, 2020

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference

Jun 1, 2020

BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting

Jun 1, 2020

EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020

May 29, 2020

Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)

May 29, 2020

RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial

May 29, 2020

ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors

May 29, 2020

MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting

May 29, 2020

Boundless Bio Presents Data Assessing the Relationship Between Extrachromosomal DNA and Biomarker Signatures Associated with Response to Checkpoint Inhibitors in Gastric Cancer at the 2020 ASCO Virtual Annual Meeting

May 29, 2020

Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation

May 29, 2020

SEngine Precision Medicine Presented Data at ASCO 2020 on Clinical Validation of the CLIA Certified PARIS Test, a Revolutionary Organoid Based Assay, to Personalize Cancer Treatments

May 29, 2020

Rakuten Medical Establishes Illuminox™ Alliance Institutes to Accelerate Development of Cancer Therapies, Announcing The National Cancer Center Japan as the First Institute to Join the Alliance

May 28, 2020

MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613 (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia

May 28, 2020

WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo) for the Treatment of Non-Small Cell Lung Cancer

May 28, 2020

Incysus Therapeutics Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

May 27, 2020

MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs

May 27, 2020

EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer

May 26, 2020

Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

May 26, 2020

Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613 (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

May 22, 2020

Global Interventional Oncology Market Analysis 2020 with Key Player Profiles Including ABK Biomedical Inc., Guerbet, Medtronic Plc and Sirtex Medical

May 21, 2020

Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors

May 21, 2020

Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity of a Potent and Selective Inhibitor of CBP/p300 for Androgen Receptor Positive Cancers to be Presented at the American Association for Cancer Research

May 21, 2020

WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

May 19, 2020

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

May 18, 2020

ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25th Congress of the European Hematology Association (EHA)

May 18, 2020

LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer

May 15, 2020

HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients

May 14, 2020

Innovative Cellular Therapeutics Announces Acceptance of Abstract on its Novel CoupledCAR Technology for Treating Colorectal Cancer for Oral Presentation at the 23rd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 14, 2020

ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2020

Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome

May 14, 2020

NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site

May 14, 2020

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

May 14, 2020

NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer

May 13, 2020

Boundless Bio Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

May 13, 2020

Arcellx to Present Preclinical Data of its Novel ARC-sparX Platform Technology in Targeting HER2+ Solid Tumors at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

May 13, 2020

SEngine Precision Medicine to Present Data Related to the Predictive Value of the PARIS Test for Oncology Drugs Based on Retrospective Analysis at 2020 ASCO Annual Meeting

May 12, 2020

POINT Biopharma Announces Phase 3 Prostate Cancer Trial

May 11, 2020

Portage Makes Additional Investment in Stimunity S.A.S, a Paris-Based Cancer Immunotherapy Company.

May 11, 2020

Senti Biosciences to Present on Gene Circuit-Based Therapies at the 2020 ASGCT Annual Meeting

May 11, 2020

Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer

May 9, 2020

F-star Therapeutics Announces Data on Potent Anti-Tumor Activity of FS120 Published in Cancer Immunology Research

May 7, 2020

Vor Biopharma Appoints Dr. Robert Pietrusko as Chief Regulatory and Quality Officer

May 7, 2020

POINT Biopharma Announces Global Prostate Oncology Therapeutic Board of Advisors

May 7, 2020

Genelux Corporation Announces Productive Type C Meeting with FDA

May 6, 2020

Avectas and ONK Therapeutics to Develop Off-the-Shelf Cancer Therapy USA - English Deutschland - Deutsch France - Français

May 5, 2020

Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613 (Devimistat) on Esophageal Cancer

May 5, 2020

Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody therapeutic

May 5, 2020

Immunomic Therapeutics Announces Appointments to its Board of Directors

May 4, 2020

ALX Oncology Announces Appointment of Rekha Hemrajani to Board of Directors

Apr 28, 2020

F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research

Apr 28, 2020

Prokarium Signs an Exclusive Option Agreement with the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois - CHUV) for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Apr 27, 2020

Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I

Apr 27, 2020

Actym Therapeutics Raises $34 Million Series A

Apr 27, 2020

ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome

Apr 23, 2020

Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins

Apr 17, 2020

STORM Therapeutics Announces Publication in Nature Reviews Cancer on the Role of RNA Modifications in Cancer by Founder Professor Tony Kouzarides

Apr 16, 2020

Cygnal Therapeutics Leader and Scientific Advisory Board Members Co-Author Paper in Cell Alongside Cancer Science Experts

Apr 16, 2020

How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are Increasingly Vulnerable to the COVID-19 Global Pandemic

Apr 14, 2020

AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment

Apr 14, 2020

Hansoh Expands AI Partnership with Atomwise after Early Success for Key Target in Therapy-Evading Cancers

Apr 9, 2020

Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer

Apr 8, 2020

Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer

Apr 7, 2020

Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT

Apr 7, 2020

Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT English English

Apr 5, 2020

Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment

Mar 31, 2020

Primmune Therapeutics Announces the Selection of PRTX007 as Its Clinical Development Candidate for COVID-19 and Oncology Indications

Mar 31, 2020

NKMax America Announces Acceptance of Three Abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 31, 2020

Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor

Mar 31, 2020

INCYSUS THERAPEUTICS TO PRESENT AT THE NYC SPRING ONCOLOGY INVESTOR CONFERENCE

Mar 30, 2020

Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda

Mar 26, 2020

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Mar 26, 2020

CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries

Mar 25, 2020

IMMUNEERING EXPANDS ONCOLOGY SCIENTIFIC ADVISORY BOARD WITH EXPERTS IN KEY CANCER SIGNALING PATHWAY

Mar 25, 2020

Cold Genesys Announces Name Change to CG Oncology

Mar 24, 2020

Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors

Mar 24, 2020

OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer

Mar 24, 2020

Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Mar 24, 2020

IASO Biotherapeutics Raises $60 Million in Series B Financing Led by GL Ventures to Advance Cell Therapies for Cancer Care

Mar 24, 2020

Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset

Mar 19, 2020

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company

Mar 19, 2020

ARECOR EXTENDS MULTI-PRODUCT COLLABORATION WITH CLINICAL STAGE BIOTECH

Mar 18, 2020

Sensei Biotherapeutics Appoints Robert Pierce, M.D., as Chief Scientific Officer

Mar 16, 2020

EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer Cells

Mar 12, 2020

F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies

Mar 11, 2020

Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs

Mar 10, 2020

POINT Biopharma and SCINTOMICS Announce License Agreement

Mar 9, 2020

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization and development collaboration

Mar 6, 2020

Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19

Mar 6, 2020

BioTheryX Appoints Professor Yinon Ben-Neriah, M.D., Ph.D., to its Scientific Advisory Board USA - English USA - English

Mar 6, 2020

BioTheryX Appoints Professor Yinon Ben-Neriah, M.D., Ph.D., to its Scientific Advisory Board

Mar 5, 2020

PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer

Mar 4, 2020

Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma Group for Development and Commercialization of Novel Immunocytokine for the Treatment of B-Cell Lymphomas in China/Asia

Mar 4, 2020

Relay Therapeutics Announces Formation of Oncology Advisory Board

Mar 3, 2020

MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL‑CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours

Mar 3, 2020

EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance

Mar 2, 2020

Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases

Mar 2, 2020

ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

Feb 28, 2020

Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer

Feb 27, 2020

BERG Files Patent Application For First In Class Small Molecule Modulators Of A Novel Target Identified By BERG's Interrogative Biology Platform

Feb 27, 2020

Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

Feb 27, 2020

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

Feb 26, 2020

Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research from the Cancer Prevention and Research Institute of Texas

Feb 25, 2020

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

Feb 25, 2020

Oncologie, Inc. Announces Collaboration with Moffitt Cancer Center to Advance the Development of Precision Medicine for the Treatment of Gastric and Gastrointestinal Cancers

Feb 20, 2020

Bolt Biotherapeutics Appoints Dr. Nils Lonberg to its Scientific Advisory Board

Feb 20, 2020

Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody HMBD-002 for Cancer Clinical Trial USA - English USA - English

Feb 20, 2020

Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody HMBD-002 for Cancer Clinical Trial USA - English India - English

Feb 18, 2020

Viracta's Precision Oncology Research in EBV+ Cancers Highlighted at 16th Annual UCSD Moores Cancer Center Symposium

Feb 18, 2020

CEOCFO Magazine interview with Machavert Pharmaceuticals CEO about taking down the KRAS cancer

Feb 14, 2020

Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board

Feb 12, 2020

ALX Oncology Announces Closing of $105 Million Series C Financing

Feb 11, 2020

WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)

Feb 11, 2020

Aro Biotherapeutics Appoints Leading Cancer Biologist Dr. Martin McMahon and Protein Structure and Design Expert Dr. Ronald Swanson to its Scientific Advisory Board

Feb 11, 2020

Phosplatin Therapeutics Presents Positive Data from Two Phase I Studies in Metastatic Castrate-Resistant Prostate Cancer Patients at the 2020 Genitourinary Cancers Symposium

Feb 11, 2020

Volastra Therapeutics Launches with $12 Million in Seed Financing to Develop Novel Metastatic Cancer Therapies

Feb 11, 2020

Global Health Sciences Fund (Quark Venture LP and GF Securities) Contributes to Volastra Therapeutics’ $12 Million Seed Financing for Company’s Development of Novel Metastatic Cancer Therapies

Feb 5, 2020

WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania

Feb 5, 2020

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

Feb 4, 2020

AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial

Jan 31, 2020

Cygnal Therapeutics Announces Scientific Advisory Board

Jan 27, 2020

EpiVax Oncology Appoints Daniel Adams as Chairman of the Board of Directors

Jan 24, 2020

BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology Platform At ASCO-GI Meeting

Jan 22, 2020

Immuneering Raises $20 Million in Oversubscribed Series A Funding

Jan 22, 2020

Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Cancer

Jan 21, 2020

Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications

Jan 21, 2020

Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613 (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 15, 2020

Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions

Jan 15, 2020

Publication in Cancer Research Demonstrates Crescendo Biologics’ Humabody VH Therapeutics Outperform Conventional Antibodies in Vivo

Jan 15, 2020

Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies with Greater Precision and Speed, under Project Nexus

Jan 14, 2020

Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Jan 14, 2020

NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein

Jan 10, 2020

PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer

Jan 10, 2020

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology

Jan 10, 2020

Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy

Jan 9, 2020

Immuneering Strengthens Executive Team With Appointment of Howard L. Kaufman, M.D., as Head of Research and Development

Jan 9, 2020

Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde

Jan 7, 2020

Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

Jan 7, 2020

Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining STP705 and Sintilimab in the US

Jan 7, 2020

ALX Oncology Appoints Peter S. García as Chief Financial Officer

Jan 7, 2020

Galecto and PharmAkea Merge to Create Strong Clinical-Stage Company Developing First-in-Class Therapeutics in Fibrosis and Cancer

Jan 7, 2020

ImmunityBio to Present at the 38th Annual J.P. Morgan Healthcare Conference

Jan 6, 2020

Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment

Dec 20, 2019

Johnson and Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer

Dec 19, 2019

Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl

Dec 19, 2019

Immuneering Appoints Scott Barrett, M.D., as Chief Medical Officer

Dec 19, 2019

WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo) for Treatment of Patients with Non-Small Cell Lung Cancer

Dec 19, 2019

Kinnate Biopharma Closes $74.5M Series B Financing

Dec 18, 2019

Zentalis Pharmaceuticals Announces FDA Clearance of the IND for Its Third Oncology Drug Candidate, ZN-c3, a WEE1 Inhibitor, and the Dosing of the First Patient in a Phase 1/2 Clinical Trial

Dec 16, 2019

ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist at 2019 San Antonio Breast Cancer Symposium

Dec 16, 2019

NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

Dec 16, 2019

Immuneering Completes $17 Million Series A Financing

Dec 12, 2019

Zhejiang Medicine and Ambrx Present Positive Top Line Data from a Phase 1a/1b Clinical Trial of ARX788 in Metastatic HER2 Positive Breast Cancer

Dec 12, 2019

WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

Dec 12, 2019

Silverback Therapeutics Announces Preclinical Data at 2019 San Antonio Breast Cancer Symposium (SABCS) Supporting Development of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies

Dec 11, 2019

Pyxis Oncology Appoints Lara Sullivan, M.D. as Chief Executive Officer and Director

Dec 11, 2019

Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium

Dec 10, 2019

Diverse Biotech takes big step toward a new class of oncology drug candidates with its proprietary CuSP-C2 conjugate synthesis platform

Dec 10, 2019

Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo (Nivolumab)

Dec 10, 2019

Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration with MSD

Dec 10, 2019

ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials

Dec 10, 2019

Bloom Science Collaborates with Cedars-Sinai Medical Center to Expand Microbiome Research and Discovery into Brain Cancer

Dec 9, 2019

Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

Dec 9, 2019

Zentalis Pharmaceuticals Raises $85 Million in Oversubscribed Series C Financing to Accelerate Internally-Developed Clinical-Stage Oncology Pipeline

Dec 7, 2019

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)

Dec 6, 2019

Denovo Biopharma Licenses Global Rights to a Novel Late-Stage Oncology Drug from Sunesis Pharmaceuticals

Dec 4, 2019

ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superagonist in Non-Muscle Invasive Bladder Cancer

Dec 4, 2019

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

Dec 4, 2019

Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium

Dec 3, 2019

Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth

Dec 3, 2019

Decipher Biosciences Achieves Major Medicare Milestone for Decipher Prostate Genomic Tests

Dec 3, 2019

Sermonix to Co-sponsor ‘Candid Conversations’ Patient Advocacy Panel With Breastcancer.org at San Antonio Breast Cancer Symposium

Nov 25, 2019

Ichnos Sciences Strengthens Board With Addition Of Marcela Maus, MD, PhD

Nov 22, 2019

SHEPHERD Names Dr. Catharine Young Executive Director of the SHEPHERD Foundation

Nov 21, 2019

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer

Nov 20, 2019

Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Nov 20, 2019

Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines

Nov 20, 2019

Boundless Bio Announces Publication in Nature Elucidating the Role of Extrachromosomal DNA (ecDNA) Structure in Cancer Biology

Nov 20, 2019

Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology USA - English USA - Deutsch USA - Français USA - español

Nov 18, 2019

AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research’s Tumor Immunology and Immunotherapy Conference

Nov 18, 2019

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck Cancer

Nov 18, 2019

MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Nov 14, 2019

ALX Oncology to Present ALX148 Clinical Data at the 61st American Society of Hematology Annual Meeting (ASH)

Nov 14, 2019

SEngine Precision Medicine Names Surgical Oncologist and Cancer Care Advocate Dr. Astrid Margossian as Chief Medical Officer

Nov 11, 2019

NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines

Nov 8, 2019

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC

Nov 8, 2019

Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting

Nov 8, 2019

Brain Cancer Patient Survival, Immune and Tumor Data from AIVITA Biomedical's Phase 2 Clinical Trial to be Presented at SITC Annual Meeting

Nov 8, 2019

Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2019

Tempest Therapeutics’ Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting

Nov 8, 2019

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC

Nov 8, 2019

Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study

Nov 8, 2019

Akoya Expands Spatial Biology Portfolio with Optimized PD-1/PD-L1 Panels for Melanoma and Lung Cancer

Nov 7, 2019

NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas

Nov 7, 2019

AgilVax to Present at the 2019 NYC Oncology Investor Conference

Nov 7, 2019

Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership

Nov 7, 2019

Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership

Nov 7, 2019

Treos Bio Presents Positive Data on Its Off-the-Shelf Shared Antigen-Based Cancer Vaccine Against Microsatellite-stable metastatic colorectal cancer and Personalized Vaccines Against Three Metastatic cancers

Nov 7, 2019

NanOlogy Clinical Updates on Local Injection of NanoPac for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas

Nov 7, 2019

Enterome Enters Research Collaboration With Major Cancer Center Focused on New Microbiome-derived Immunotherapies

Nov 7, 2019

Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific and Medical Affairs Industry Membership

Nov 7, 2019

South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance RandD Across Two Separate Programs for Oncology

Nov 6, 2019

ALX Oncology Presents Clinical Biomarker Data from ALX148 Clinical Trial Solid Tumor Combination Cohorts at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 6, 2019

Ervaxx Launches to Pioneer the Use of Dark Antigens™ for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies

Nov 6, 2019

Primmune Therapeutics Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2019

SITC 2019: Forbius to Report Phase 1a Oncology Clinical Data with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor, in Late-Breaking Poster Presentation

Nov 5, 2019

WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to Peripheral Blood Counterparts at 34th Annual Meeting of the Society for Immunotherapy of Cancer

Nov 5, 2019

ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer

Nov 5, 2019

Checkmate Pharmaceuticals Presents Positive Clinical Data with CMP-001 at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC)

Nov 5, 2019

EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer

Nov 5, 2019

SITC 2019: Forbius to Report Phase 1a Oncology Clinical Data with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor, in Late-Breaking Poster Presentation

Nov 5, 2019

Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Nov 5, 2019

Bolt Biotherapeutics Announces ISAC Data Presentation At the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 4, 2019

ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research

Nov 4, 2019

Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients

Nov 4, 2019

Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

Nov 1, 2019

AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November

Nov 1, 2019

Checkmate Pharmaceuticals Announces Data Presentations for Lead Program at The 34th Annual Meeting of The Society for Immunotherapy of Cancer

Oct 31, 2019

Eureka Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Oct 31, 2019

RareCyte expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit

Oct 30, 2019

RareCyte launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis

Oct 30, 2019

AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR-T cells for Patients with Advanced, Refractory Thyroid Cancer

Oct 29, 2019

Gotham Therapeutics Establishes Advanced Oncology Profiling Cascade with ProQinase to Progress its Portfolio of Epitranscriptomic Drug Candidates

Oct 29, 2019

Tolero Pharmaceuticals Presents Findings from Preclinical Studies Evaluating Investigational Agents TP-1287 in Prostate Cancer Models and TP-1454 in Colorectal Cancer Models

Oct 29, 2019

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer

Oct 28, 2019

Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds

Oct 28, 2019

Prelude Therapeutics expands in Delaware; Adding biotech jobs in cancer drug discovery research

Oct 25, 2019

Neopharma Forms Joint Venture With Elevar Therapeutics for Commercialization of Oncology NCE

Oct 25, 2019

LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study

Oct 24, 2019

Tarveda Therapeutics Publishes Results of Preclinical Studies Evaluating PEN-221 as a Treatment for Small Cell Lung Cancer in Molecular Cancer Therapeutics

Oct 24, 2019

Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical's Phase 2 Clinical Trial

Oct 24, 2019

Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer

Oct 24, 2019

Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Oct 23, 2019

EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)

Oct 22, 2019

Nurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

Oct 22, 2019

Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2019

Systems Oncology Receives Investment from The Pritzker Organization

Oct 21, 2019

Propanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer Patients

Oct 17, 2019

Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 17, 2019

Immunomic Therapeutics to Present at Precision Lung Cancer World R&D Summit

Oct 17, 2019

Immunomic Therapeutics to Present at Precision Lung Cancer World RandD Summit

Oct 17, 2019

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

Oct 16, 2019

Pyxis Oncology Appoints Pharmaceutical Industry Veteran Ronald Herbst, PhD, as Chief Scientific Officer

Oct 16, 2019

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer

Oct 15, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Oct 15, 2019

NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®

Oct 15, 2019

NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac

Oct 9, 2019

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

Oct 8, 2019

Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Oct 8, 2019

Bolt Biotherapeutics Announces Scientific Advisory Board with the Appointment of Drs. Larry Fong, Roy Herbst and Bruce Roth

Oct 7, 2019

Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast Cancer

Oct 2, 2019

ALX Oncology to Present ALX148 Clinical Biomarker Data at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 2, 2019

SEngine Precision Medicine Raises $5.1 Million Series A to Advance Personalized Oncology Drug Discovery Platform

Oct 1, 2019

AIVITA Biomedical to Present at Meeting on the Mesa and Other Investor, Oncology and Regenerative Medicine Conferences in October

Oct 1, 2019

Tmunity Announces Exclusive License and Research Collaboration with Children’s Hospital of Philadelphia to Advance GPC2 CAR-T Cell Therapy for Neuroblastoma

Oct 1, 2019

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Center

Oct 1, 2019

Numab and Eisai Enter Into a Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Sep 30, 2019

Tarveda Therapeutics Presents Data from the Phase 1 Portion of a Phase 1/2a Study of PEN-866 at the European Society for Medical Oncology (ESMO) Congress 2019

Sep 30, 2019

MiNA Therapeutics Presents Clinical and Pre-Clinical Data at ESMO Supporting MTL-CEBPA as Immunological Combination Treatment

Sep 30, 2019

Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 and 1/2a Clinical Trials USA - English Nederland - Nederlands España - español

Sep 30, 2019

ITM and Bruce Power Successfully Complete Feasibility Study

Sep 30, 2019

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

Sep 26, 2019

Black Diamond Therapeutics to Present Preclinical Data on its Lead Product Candidate BDTX-189 at the European Society for Medical Oncology 2019

Sep 26, 2019

Vigeo Therapeutics to Present Results from Its Phase 1 Study Evaluating VT1021 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology (ESMO) 2019 Congress

Sep 26, 2019

Treos Bio Reports Updated Positive Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer

Sep 25, 2019

OncoQuest Receives "Notice of Allowance" for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients

Sep 25, 2019

Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting

Sep 25, 2019

OCTIMET Expands Ongoing Proof of Concept Study to Evaluate the Combination of Highly Selective MET Kinase Inhibitor OMO-1 with EGFR TKIs

Sep 24, 2019

Apexigen Announces Participation In Upcoming Oncology Conferences

Sep 24, 2019

Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

Sep 23, 2019

Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Sep 23, 2019

AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

Sep 23, 2019

I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA (pembrolizumab) in Patients with Multiple Cancer Types

Sep 19, 2019

Black Diamond Therapeutics Names Christopher Roberts, Ph.D., as Chief Scientific Officer

Sep 19, 2019

Context Therapeutics and Jefferson Health to Evaluate Apristor Combination Therapy for Women with Advanced Endometrial Cancer

Sep 19, 2019

Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)

Sep 19, 2019

Boundless Bio Launches to Deliver Transformative Therapies to Patients with Difficult-to-Treat Cancers Driven by Extrachromosomal DNA

Sep 17, 2019

Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

Sep 16, 2019

Rgenix Names Industry Veteran to Chief Medical Officer Role

Sep 16, 2019

Context Therapeutics and SOLTI launch ONAWA: a Window of Opportunity Study in Breast Cancer with Apristor

Sep 16, 2019

LIPAC Oncology and Huons Co. Announce Exclusive Licensing Agreement for TSD-001 in Korea

Sep 16, 2019

Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and Forms Research Collaboration to Develop Allogeneic T-cell Therapeutics for Cancer

Sep 13, 2019

Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor

Sep 11, 2019

Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients

Sep 10, 2019

SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery

Sep 10, 2019

Linnaeus Therapeutics Scientific Cofounder Presents Preclinical Pancreatic Cancer Data at AACR Pancreas Cancer Meeting

Sep 10, 2019

Atomwise and OncoStatyx Announce Joint Venture to Develop Small Molecule Inhibitors of Oncology Target KDM5B

Sep 9, 2019

KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients USA - English USA - English

Sep 9, 2019

KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

Sep 4, 2019

Repare Therapeutics Announces US$82.5 Million Series B Financing

Sep 4, 2019

Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor

Aug 28, 2019

Emmaus Life Sciences Adds Oncology Supply as Distributor

Aug 28, 2019

HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders

Aug 27, 2019

Harbour BioMed and PPD Form Strategic Collaboration to Develop Innovative Therapeutics for Oncology and Immunology

Aug 14, 2019

Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trial

Aug 13, 2019

NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer

Aug 12, 2019

Arch Oncology Appoints Drew Dennison to Board of Directors

Aug 12, 2019

TScan Therapeutics Announces Pioneering Publication in Scientific Journal Cell Describing New Methods to Identify Targets for T Cell Receptor Immunotherapy

Aug 12, 2019

Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer

Aug 9, 2019

EnGeneIC Wins Innovation Award from Australian Financial Review

Aug 8, 2019

ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance

Aug 7, 2019

Xynomic Pharma Receives Important Accreditation from Independent Ethics Committees of Leading Chinese Cancer Hospitals

Aug 6, 2019

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board

Aug 6, 2019

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board India - English USA - English

Aug 5, 2019

Eureka Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of ET140202 ARTEMIS™ T-Cell Therapy in Liver Cancer

Aug 2, 2019

Antikor Biopharma and Essex Bio-Technology Forge Strategic Alliance in FDC for Cancer Treatment

Jul 31, 2019

Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office

Jul 29, 2019

QUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors

Jul 18, 2019

Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

Jul 17, 2019

Pyxis Oncology Founded by Longwood Fund with Financing Led by Bayer

Jul 17, 2019

Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeutics

Jul 16, 2019

Skyhawk Therapeutics Announces Agreement with Genentech to Discover and Develop Small Molecule RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases

Jul 16, 2019

Cyclica and University of Toronto Stagljar Lab Announce Partnership to Create the Next-Generation EGFR Inhibitors in Non-Small Cell Lung Cancer

Jul 16, 2019

Skyhawk Therapeutics Announces Agreement with Genentech to Discover and Develop Small Molecule RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases USA - English USA - Français USA - español USA - Deutsch

Jul 15, 2019

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Jul 15, 2019

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Jul 10, 2019

TARIS Initiates Clinical Trial of TAR-200 in Combination with Opdivo® (nivolumab) for Patients with Muscle-Invasive Bladder Cancer

Jul 10, 2019

Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

Jul 9, 2019

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

Jul 9, 2019

WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)

Jul 9, 2019

Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery

Jul 8, 2019

Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology

Jul 8, 2019

AIVITA Biomedical Announces New Clinical Data in Ongoing Phase 2 Brain Cancer Trial

Jul 8, 2019

Skyhawk Therapeutics Announces Addition of World Leading SAB Head and New VP of Oncology Biology USA - English USA - Français USA - Deutsch USA - español

Jul 1, 2019

Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform

Jun 27, 2019

Global Cancer Stem Cell Therapeutics Market to 2023 - Led by Cellerant Therapeutics, Celularity, Gamida Cell, Nohla Therapeutics, and Sumitomo Dainippon Pharma Co

Jun 27, 2019

Vycellix Founders Awarded Innovation Grant by Sweden’s Vinnova to Establish New World-Class Research Environment on Development of Next-Generation Natural Killer Cell-based Cancer Immunotherapy

Jun 27, 2019

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

Jun 26, 2019

TARIS Announces Positive Results of Phase 1b Trial of TAR-200 in Muscle Invasive Bladder Cancer

Jun 25, 2019

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

Jun 25, 2019

Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries

Jun 25, 2019

Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613 (devimistat) in Japan and Other Asian Countries

Jun 24, 2019

Atomwise and Enamine to Advance Pediatric Oncology With the World’s First and Largest Ten Billion Compound Virtual Screen

Jun 20, 2019

Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis

Jun 20, 2019

Cancer Prevention Pharmaceuticals (CPP) Reports FAP Phase 3 Clinical Trial Results at Digestive Disease Week Conference

Jun 19, 2019

Nouscom Demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in Combination With Immune Checkpoint Blockade to Eradicate Large Tumors

Jun 19, 2019

Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

Jun 19, 2019

Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

Jun 18, 2019

FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501

Jun 14, 2019

RNA Blockade to Treat Triple Negative Breast Cancer

Jun 12, 2019

Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer

Jun 12, 2019

Prelude Therapeutics Secures $60 Million and Expands Management Team to Develop Drugs Targeting Novel Molecular Mechanisms in Cancer

Jun 11, 2019

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT

Jun 4, 2019

Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform

Jun 4, 2019

Origenis GmbH Announces Research Collaboration with U.S. Cancer Center

Jun 3, 2019

Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)

Jun 3, 2019

Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

Jun 3, 2019

BERG Presents Key Findings From Two Important Clinical Initiatives At The 2019 ASCO Annual Meeting: BERG's Final Phase 1 Results For BPM 31543 In Chemotherapy-Induced Alopecia And A Clinical Study Using BERG's Interrogative Biology® Platform Demonstrating The Importance Of Altruism In Pancreatic Cancer Biomarker Discovery

Jun 3, 2019

Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent Malignant Gliomas

Jun 3, 2019

Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations

Jun 3, 2019

HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer

Jun 1, 2019

ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors

Jun 1, 2019

Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

May 31, 2019

ALX Oncology to Present at Jefferies 2019 Healthcare Conference

May 31, 2019

Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO

May 29, 2019

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

May 29, 2019

Cytonus Therapeutics to Present CA-IL12 Breast Cancer Data at the 2019 BIO International Convention

May 28, 2019

Nanobiotix Announces the Launch of Curadigm: a New Nanotechnology Platform for Healthcare

May 28, 2019

Treos Bio Announces Positive Interim Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer

May 28, 2019

Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene

May 26, 2019

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer

May 26, 2019

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA in Triple-Negative Breast Cancer

May 24, 2019

FLX Bio Announces Name Change to RAPT Therapeutics

May 24, 2019

NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™ with Vaccines in Elderly Cancer Survivors

May 22, 2019

Arch Oncology Appoints Kirk Christoffersen as Chief Business Officer

May 21, 2019

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

May 21, 2019

Xynomic Pharma To Present Long-Term Follow Up Data Showing Abexinostat, Combined with Pazopanib, has Durable Responses in Patients with Pre-Treated Kidney Cancer

May 21, 2019

Xynomic Pharma To Present Long-Term Follow Up Data Showing Abexinostat, Combined with Pazopanib, has Durable Responses in Patients with Pre-Treated Kidney Cancer

May 20, 2019

Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer

May 20, 2019

Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation

May 17, 2019

Ligand Licenses VER250840 to Cumulus Oncology

May 17, 2019

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

May 17, 2019

iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer

May 16, 2019

ALX Oncology to Present ALX148 Clinical Data at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

May 16, 2019

Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract

May 16, 2019

Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala

May 16, 2019

Adastra Pharmaceuticals Announces that Data from Phase 1b Clinical Trial of Zotiraciclib Will Be Presented at ASCO 2019

May 16, 2019

Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting

May 16, 2019

Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

May 15, 2019

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

May 14, 2019

CORRECTING and REPLACING NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response

May 14, 2019

Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium

May 14, 2019

CORRECTING and REPLACING NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac Resulted in Increased Tumor Regression and Immune Response

May 13, 2019

ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies

May 13, 2019

ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer

May 9, 2019

Rainier Therapeutics Announces Upcoming Oral and Poster Presentation on Vofatamab at AACR Bladder Cancer Conference

May 9, 2019

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy

May 9, 2019

NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce for Treatment of Bladder Cancer

May 9, 2019

Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma

May 7, 2019

Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis

May 6, 2019

PIN Pharma to Present a Poster at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 5, 2019

Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics

May 3, 2019

NeoImmuneTech, Genexine, SNUH and POSTECH researchers Announce Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

May 2, 2019

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological Cancers

May 2, 2019

QUE Oncology Launches Phase II Trials in the United States

May 2, 2019

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor in Progesterone Receptor Positive Gynecological Cancers

May 1, 2019

IO Biotech to Participate in Panel Discussion at 30th Annual Cancer Progress Conference in New York

May 1, 2019

Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers

Apr 26, 2019

Sirnaomics Closes $47 Million Series C Financing to Develop RNAi Therapeutics for Treatment of Cancer and Fibrotic Diseases

Apr 25, 2019

Rainier Therapeutics Announces Vofatamab Data Accepted for Presentation at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2019

Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumor-targeted Bispecific Bicycles at Peptides Congress

Apr 23, 2019

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA in Spain

Apr 22, 2019

Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

Apr 18, 2019

Arrakis Therapeutics Announces $75 Million Series B Financing to Advance a New Class of Small-Molecule Medicines Targeting RNA

Apr 17, 2019

Kiadis to Acquire Cytosen Therapeutics, Inc.

Apr 17, 2019

SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer

Apr 16, 2019

Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program USA - English USA - English

Apr 16, 2019

Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program

Apr 15, 2019

Sensei Biotherapeutics Appoints Former Head of the National Cancer Institute, Samuel Broder, M.D. to its Board of Directors

Apr 15, 2019

Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer

Apr 11, 2019

Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board

Apr 9, 2019

NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer

Apr 8, 2019

IGF Oncology Appoints Gary G. Altman, Ph.D., as Chief Executive Officer

Apr 8, 2019

Entrepreneurs from Ontario's Nanology Labs and Xpan Inc. receive FACIT investment for early-stage cancer innovations

Apr 4, 2019

SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)

Apr 2, 2019

ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Mediated Cancer Treatment Resistance at the AACR Annual Meeting

Apr 2, 2019

MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR

Apr 2, 2019

Actym Therapeutics Will Present Data at the 2019 American Association for Cancer Research Annual Meeting

Apr 2, 2019

ITM and United Imaging team up in strategic partnership to cover Chinese and global cancer imaging markets

Apr 1, 2019

Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer

Apr 1, 2019

SpringWorks Therapeutics Completes $125 Million Series B Financing

Apr 1, 2019

Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium

Apr 1, 2019

IO Biotech Presents Data on an Immunomodulatory CCL22-based Vaccine at the American Association for Cancer Research Annual Meeting 2019

Apr 1, 2019

BERG Presents Novel Mechanism Underlying BPM 31510 in Glioblastoma and Identification of Prostate and Pancreatic Cancer Biomarkers at 2019 AACR Meeting

Apr 1, 2019

Torque Presents New Preclinical Data for its Deep-Primed Cellular Immunotherapy Programs at the American Association for Cancer Research (AACR) Annual Meeting

Apr 1, 2019

Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

Apr 1, 2019

PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

Apr 1, 2019

Turning Point Therapeutics’ Kinase Inhibitors Show High Potency against Targeted Oncogene Drivers and Their Mutations

Apr 1, 2019

Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019

Apr 1, 2019

Primmune Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019

Apr 1, 2019

Bolt Biotherapeutics Presents Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference

Mar 31, 2019

Apexigen Announces New Clinical Data On APX005M In Combination Therapy For Pancreatic Cancer At The AACR Annual Meeting 2019

Mar 31, 2019

F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies

Mar 29, 2019

Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting

Mar 29, 2019

Arch Oncology to Present Preclinical Data on Highly-Differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019

Mar 29, 2019

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting

Mar 29, 2019

Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting

Mar 29, 2019

Machavert Pharmaceuticals Will Present at the Annual Meeting of the American Association of Cancer Research (AACR)

Mar 29, 2019

Boehringer Ingelheim Enhances Oncology RandD with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Mar 28, 2019

Cytonus Therapeutics Announces Poster Presentation at the 2019 American Association for Cancer Research Annual Meeting

Mar 27, 2019

Enterome to Present Data on Its Innovative Microbiome-derived Molecular Mimicry Approach to Cancer Immunotherapy at AACR 2019

Mar 26, 2019

Lipella Pharmaceuticals Received FDA IND Approval for Phase-2a Oncology Supportive Care Drug Study

Mar 26, 2019

Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

Mar 26, 2019

Cancer Biotech Firm Alpha Tau Medical Appoints Raphi Levy of Goldman Sachs as Chief Financial Officer

Mar 26, 2019

Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target

Mar 25, 2019

Arch Oncology Raises $50 Million Series B Financing

Mar 25, 2019

Portage makes additional investment in Stimunity S.A, a Paris-based cancer immunotherapy company.

Mar 25, 2019

Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting

Mar 25, 2019

EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

Mar 21, 2019

Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting

Mar 21, 2019

CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019

Mar 21, 2019

CureVac kündigt Late-Breaking-Posterpräsentation mit neuesten Daten anlässlich der Jahreskonferenz 2019 der American Association of Cancer Research (AACR) an

Mar 20, 2019

Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer

Mar 20, 2019

Enterome Announces Research Collaboration with Renowned US Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy

Mar 19, 2019

Nurix Therapeutics to Present at 2019 American Association for Cancer Research (AACR) Annual Meeting

Mar 19, 2019

Rain Therapeutics Announces First Patient Dosed in Phase 2 Trial of Tarloxotinib for the Treatment of Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertion or HER2-Activating Mutations

Mar 16, 2019

Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials

Mar 15, 2019

Vycellix CEO to Present Strategies for Enhancing Next-Generation NK Cell Cancer Therapy at Innate Killer Summit

Mar 13, 2019

Global Non-Small Cell Lung Cancer Pipeline Therapeutics Report 2019 - ResearchAndMarkets.com

Mar 13, 2019

Propanc Biopharma Receives Notice of Allowance for Additional Claims from Foundation Patent in the U.S.

Mar 11, 2019

Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment

Mar 5, 2019

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

Mar 5, 2019

Bexion Pharmaceuticals Experiences Robust Enrollment of Phase I Part 3 First-In-Human Trial Using BXQ-350 for the Treatment of Cancer

Mar 4, 2019

Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer

Mar 1, 2019

AIVITA Biomedical to Present Cancer Vaccine Data at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Feb 28, 2019

Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting

Feb 28, 2019

Immunomic Therapeutics Announces Late-Breaking Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019

Feb 28, 2019

SQZ Biotech to Present at the American Association for Cancer Research (AACR) 2019 Annual Meeting

Feb 27, 2019

ALX Oncology to Present Preclinical Data on SIRPα Antibody Program at Upcoming Conferences

Feb 27, 2019

Silverback Therapeutics to Present Data for Lead Therapeutic Candidate SBT6050 at American Association of Cancer Research Annual Conference

Feb 27, 2019

Bolt Biotherapeutics To Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference

Feb 25, 2019

Sirnaomics to Present Data Demonstrating STP705 Augmentation of Immune Checkpoint Inhibitors in Liver Cancer Animal Model at AsiaTIDES

Feb 25, 2019

Hummingbird Bioscience Awarded $13.1 Million Grant by the Cancer Prevention and Research Institute of Texas (CPRIT)

Feb 22, 2019

Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

Feb 21, 2019

Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies

Feb 20, 2019

Torque Announces Clinical Trial Collaboration with Merck

Feb 14, 2019

Decipher Biosciences Announces its Genomic Data Featured at 2019 Genitourinary Conference in Multiple Prostate Cancer Presentations

Feb 13, 2019

IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board

Feb 7, 2019

Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody, for Reducing Lung Cancer in High Risk Smokers

Feb 7, 2019

HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics

Feb 6, 2019

Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile

Feb 5, 2019

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

Feb 5, 2019

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor English Deutsch Français español

Jan 30, 2019

Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute

Jan 30, 2019

Eureka Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Trial of ET140202 Artemis T-Cell Therapy, for the Treatment of Liver Cancer

Jan 29, 2019

Propanc Biopharma to Present at the 2019 BIO CEO and Investor Conference

Jan 28, 2019

EpimAb Biotherapeutics Achieves Key Milestone with Lead Cancer Program EMB01

Jan 25, 2019

OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

Jan 23, 2019

B-MoGen Biotechnologies and CytoSen Therapeutics partner on research collaboration to develop next generation Natural Killer Cells for human therapeutics

Jan 22, 2019

Cybrexa Therapeutics Announces Multiple Oral Presentations Highlighting the Advances in the Application of DNA Repair Pathways in Cancer Drug Development at the DNA Damage Response Therapeutics Summit 2019

Jan 17, 2019

Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium

Jan 16, 2019

AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial

Jan 14, 2019

Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar

Jan 10, 2019

Black Diamond Therapeutics Closes $85 Million Series B Financing

Jan 10, 2019

EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613) for Treatment of Metastatic Pancreatic Cancer

Jan 9, 2019

Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Jan 9, 2019

EUSA Pharma Completes Acquisition of Global Rights to SYLVANT (Siltuximab) and Presents Company Update at 37th J.P. Morgan Healthcare Conference

Jan 8, 2019

Systems Oncology to Present at eChinaHealth Event During the 37th Annual J.P. Morgan Healthcare Conference

Jan 7, 2019

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Jan 7, 2019

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 and 3 Inhibitor

Jan 6, 2019

Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development

Jan 4, 2019

Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer

Jan 4, 2019

Flex Pharma and Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Therapy for Cancer

Jan 4, 2019

Numab Builds Out Clinical Advisory Board with High Profile Appointments

Jan 3, 2019

Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer

Jan 3, 2019

Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer

Jan 3, 2019

AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

Dec 28, 2018

InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer

Dec 27, 2018

Xynomic Pharma Will Present at ASCO-GU Cancers Symposium, Files 3 INDs for Potentially Pivotal Cancer Trials in China, and Expands R&D Operations

Dec 20, 2018

IGF Oncology to Present at Biotech Showcase 2019

Dec 20, 2018

Distinguished Breast Cancer Expert, Dr. George W. Sledge, Jr., M.D., to join the Board of Tessa Therapeutics

Dec 20, 2018

Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705 for the Treatment of Non-Melanoma Skin Cancer

Dec 18, 2018

Propanc Biopharma Selects LaVoieHealthScience as Integrated Communications Partner

Dec 17, 2018

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

Dec 14, 2018

Systems Oncology Announces Pipeline of Innovative Drugs Emerging from the Use of Artificial Intelligence

Dec 14, 2018

Astellas Acquires Potenza Therapeutics

Dec 11, 2018

Versant Ventures Launches Black Diamond Therapeutics

Dec 11, 2018

Aro Biotherapeutics Raises $13 Million and Establishes Leadership Team to Develop Next Generation of Protein Therapeutics

Dec 11, 2018

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer

Dec 10, 2018

Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis

Dec 10, 2018

Immix Observes Clinical Benefit at Dose-Level 2 in Phase 1b Clinical Trial in Refractory Cancer

Dec 10, 2018

Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Dec 10, 2018

CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors

Dec 10, 2018

CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer

Dec 10, 2018

HiFiBiO Therapeutics and Vikas Sukhatme Join Forces to Discover and Develop Novel Antibody Treatments for Cancer

Dec 8, 2018

Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Nov 30, 2018

Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform

Nov 29, 2018

Bio-Thera Solutions Announces BAT8001 (HER2-ADC) and BAT8003 (Trop2-ADC) Poster Presentations at the 2018 San Antonio Breast Cancer Symposium

Nov 28, 2018

twoXAR Receives $225K Phase I SBIR Grant for Pancreatic Cancer Drug Discovery

Nov 28, 2018

CORRECTING and REPLACING Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System

Nov 27, 2018

Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

Nov 27, 2018

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Nov 27, 2018

ADC Therapeutics annonce les premiers patients traités dans le cadre de l'essai clinique de Phase I/II sur ADCT-602 dans le traitement de la leucémie aigüe lymphoblastique à lymphocytes B en rechute ou réfractaire

Nov 27, 2018

ADC Therapeutics gibt erste behandelte Patienten in klinischer Studie der Phase I/II zu ADCT-602 bei rezidivierter oder refraktärer akuter lymphatischer B-Zell-Leukämie bekannt

Nov 26, 2018

Machavert Pharmaceuticals Unveils a New Bioactive Lipid Drug Candidate for Cancer Treatment

Nov 26, 2018

Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer

Nov 26, 2018

CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical Enter into a Collaboration and License Agreement to Develop Combination Cancer Treatments

Nov 22, 2018

Vineti™ to Partner With Tessa Therapeutics™ to Advance and Scale Cancer Immunotherapies World-Wide

Nov 19, 2018

Cancer Prevention Pharmaceuticals to Present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018

Nov 15, 2018

Atreca to Present Analyses of Active B Cell Responses in Nearly 200 Cancer Patients Leading to Identification of More Than 1,000 Antibodies Targeting Non-Autologous Tumor

Nov 15, 2018

PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors

Nov 15, 2018

Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors

Nov 15, 2018

AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA

Nov 15, 2018

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Nov 14, 2018

Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

Nov 13, 2018

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

Nov 13, 2018

Ascentage Pharma Presenting New Clinical Data of Novel Dual Bcl-2/Bcl-xL Inhibitor APG-1252 at Asia Conference on Lung Cancer 2018 (ACLC)

Nov 13, 2018

DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer

Nov 13, 2018

Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies

Nov 12, 2018

Bicycle Therapeutics’ Founder Sir Gregory Winter to Deliver Keynote Address at the 2018 Protein and Antibody Engineering (PEGS) Summit Europe

Nov 9, 2018

GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

Nov 9, 2018

TARIS Announces Late-Breaking Poster on the Natural History of Muscle-Invasive Bladder Cancer Patients Not Receiving Potentially Curative Therapy

Nov 8, 2018

Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Nov 8, 2018

Actym Therapeutics Will Present Data at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2018

Tarveda Therapeutics to Present at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Nov 8, 2018

ADC Therapeutics kündigt Präsentationen auf der 33. Jahrestagung der Society for Immunotherapy of Cancer (SITC) an

Nov 8, 2018

ADC Therapeutics annonce des présentations à la 33e conférence annuelle de la Society for Immunotherapy of Cancer (SITC)

Nov 7, 2018

Alpha Tau Medical Launches New Clinical Trials in Italy with Leading Cancer Centers, La Sapienza and IFO

Nov 7, 2018

AIVITA Biomedical to Exhibit ROOT OF CANCER Immunotherapy at 33rd SITC Annual Meeting

Nov 7, 2018

ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors

Nov 7, 2018

Effectiveness of DNAtrix's DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

Nov 7, 2018

CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Nov 6, 2018

Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Nov 6, 2018

Atreca to Present Data Further Demonstrating Ability of the Company’s Discovery Engine to Identify Patient-Derived Antibodies that Target Non-Autologous Tumor Tissue

Nov 6, 2018

Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

Nov 5, 2018

Cybrexa Therapeutics to Present Preclinical Data for its Tumor-Selective Technology Platform at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Nov 1, 2018

WUGEN Announces Presentations at American Society of Hematology Annual Meeting

Nov 1, 2018

Bio-Thera Solutions Announces Initiation of Pivotal Phase III Study of BAT8001 for Patients with Metastatic Breast Cancer

Oct 30, 2018

Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer

Oct 29, 2018

NeoImmuneTech Announces Initiation of Clinical Trial for HyLeukin-7 Treatment in Combination with Standard Therapy for Newly Diagnosed Brain Cancer Patients

Oct 29, 2018

SEngine Precision Medicine Announces Nobel Prize Winner and Former Fred Hutch Cancer Research Center President Dr. Leland Hartwell to Join Board of Directors

Oct 28, 2018

Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World RandD Summit

Oct 26, 2018

Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit

Oct 25, 2018

Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy

Oct 23, 2018

Immunomic Therapeutics CEO to Present at NYC Oncology Investor Conference

Oct 23, 2018

Integral Molecular Receives NIAID Award to Combat COVID-19

Oct 23, 2018

Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

Oct 23, 2018

Arcellx Presents Preclinical Data for ARC-sparX Platform Technology in Targeting CD123-Positive AML Tumors

Oct 23, 2018

enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis

Oct 23, 2018

Talaris Therapeutics Adds Two Experienced Biotechnology Executives to its Board of Directors

Oct 23, 2018

Ribon Therapeutics Announces Upcoming Presentations at the AACR 2021 Virtual Annual Meeting

Oct 23, 2018

Betagenon AB announces investment and collaboration with Hong Kong-based MCG Technology Group Ltd

Oct 23, 2018

Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer

Oct 23, 2018

Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome

Oct 23, 2018

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC

Oct 23, 2018

Aerium Therapeutics launches to develop novel therapeutics against COVID-19 and future pandemic threats

Oct 22, 2018

EpiVax Oncology Appoints Dominique Bridon as Chief Technology Officer and Dan Adams to the Board of Directors

Oct 22, 2018

AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

Oct 19, 2018

BERG to Present New Data Describing Details on Progress of its Oncology Portfolio and Precision Medicine Applications at the European Society for Medical Oncology 2018 Congress

Oct 19, 2018

QED Therapeutics Presents Data for Infigratinib in Cholangiocarcinoma in Late Breaking Abstract at the European Society of Medical Oncology 2018 Congress

Oct 19, 2018

Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

Oct 17, 2018

Batu Biologics Recruits Dr. Vijay Mahant as the Vice President of Precision Oncology to Oversee the Personalization of ValloVax Immunogenicity

Oct 16, 2018

REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

Oct 16, 2018

eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR's Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer

Oct 15, 2018

Phyton Biotech Partners with PellePharm to Develop Renewable Supply of Cyclopamine for Investigational Topical Cancer Therapy

Oct 12, 2018

AIVITA Biomedical Attains Japanese PMDA Milestone for ROOT OF CANCER Technology

Oct 11, 2018

Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman

Oct 10, 2018

AUM LifeTech, CHOP and Penn Partnering to Advance Cancer Immunotherapy Against Lung Cancer Using Foxp3 Gene Silencing FANA ASO Therapy

Oct 9, 2018

Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs

Oct 9, 2018

Sensei Biotherapeutics to Present Clinical Data at Upcoming Oncology Medical Conferences

Oct 9, 2018

REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

Oct 9, 2018

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer

Oct 9, 2018

Oblique Therapeutics Present Tumor Growth Inhibition and Treg-lowering Data for OT-1096 in Humanized Mouse TNBC Model at Oncology Congress ESMO

Oct 8, 2018

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Experts to its Scientific Advisory Board

Oct 8, 2018

Cybrexa Therapeutics Appoints Keely Zipp as Vice President of Marketing 

Oct 8, 2018

eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies

Oct 8, 2018

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Experts to its Scientific Advisory Board USA - English USA - Français USA - Deutsch USA - español

Oct 2, 2018

GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment

Oct 2, 2018

CureLab Oncology publishes proof of concept demonstrating that its product can reduce the leading cause of age-related blindness

Oct 2, 2018

Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer

Oct 1, 2018

Tomorrow: Immunomic Therapeutics CEO at Outsourcing in Clinical Trials Mid-Atlantic

Sep 28, 2018

KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD-1 Resistant Solid Tumors

Sep 27, 2018

IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer

Sep 20, 2018

AIVITA Biomedical Announces Treatment of First Patient in Phase 2 Ovarian Cancer Trial

Sep 19, 2018

MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference

Sep 19, 2018

Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech Conference

Sep 19, 2018

Immunomic Therapeutics Senior Vice President of RandD to Participate in Bio+Tech Conference

Sep 18, 2018

BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program

Sep 18, 2018

CBT Pharmaceuticals Initiates the APOLLO Oncology Clinical Trials Program

Sep 13, 2018

CARsgen Therapeutics and CrownBio complete CAR-T study for gastric cancer

Sep 12, 2018

Systems Oncology Announces the ExpansiveAI Project to Advance Artificial Intelligence Capable of Imagination

Sep 5, 2018

Eureka Therapeutics Achieves Regression of Metastatic Liver Cancer Using ET140202 T-cell Therapy

Sep 5, 2018

Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate Combination Therapy with CMP-001 and Avelumab

Sep 5, 2018

Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer

Sep 2, 2018

NanOlogy™ Unveils Positive Preclinical Data for Inhaled NanoPac in the Treatment of Lung Cancer

Aug 24, 2018

Forbius (Formation Biologics) Awarded $18.8 Million Grant by the Cancer Prevention and Research Institute of Texas

Aug 23, 2018

ApoGen Biotechnologies Expands Series A Financing to $11 Million and Enhances Leadership Team

Aug 20, 2018

Batu Biologics Identifies Gene Types Associated with Response to ValloVax

Aug 19, 2018

Harbour BioMed Announces Global Strategic Partnership with Kelun-Biotech to Develop and Commercialize A167, An Anti-PD-L1 Antibody, for Treatment of Cancer

Aug 16, 2018

Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma

Aug 14, 2018

AIVITA Biomedical Announces Initiation of First Clinical Site for ROOT OF CANCER Glioblastoma Trial

Aug 13, 2018

Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt

Aug 8, 2018

Context Therapeutics Signs Strategic Research Collaborations for Apristor® (onapristone extended release) With Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields

Aug 8, 2018

Context Therapeutics Signs Strategic Research Collaborations for Apristor (onapristone extended release) With Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields

Aug 8, 2018

OncoPep Announces a Phase 1b Clinical Trial of Its Multi-Peptide Cancer Vaccine PVX-410 in Combination with Citarinostat for Smoldering Multiple Myeloma

Aug 7, 2018

Agilvax Awarded $2.3 Million SBIR Fast Track Grant to Advance the Development of AX09 for Triple Negative Breast Cancer

Aug 6, 2018

Applied BioMath, LLC Extends Collaboration into Phase 1 with Northern Biologics for Clinical Pharmacology Support and Semi-Mechanistic PK/PD Modeling Support in Oncology

Aug 6, 2018

Immix Observes Complete Response in Late-Stage Canine Cancer Patient and Doses First Two Patients in Human Phase 1b/2a Study

Aug 2, 2018

Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Aug 1, 2018

Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib in Combination with Nivolumab for Treatment of Non-Small Cell Lung Cancer or Thymic Carcinoma

Jul 27, 2018

Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer

Jul 26, 2018

Propanc Biopharma Enters National Phase for Two Key Patents

Jul 18, 2018

EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ireland UC for $115 Million

Jul 13, 2018

Rafael Pharmaceuticals Appoints Two Prominent Gastrointestinal Oncologists from Europe to its Medical Advisory Board to Support Global Development of CPI-613 in Pancreatic Cancer and Other Gastrointestinal Malignancies

Jul 11, 2018

EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, QARZIBA▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

Jul 6, 2018

Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy

Jun 26, 2018

Istari Oncology Announces New England Journal of Medicine Publication of Phase 1 Trial Results in Patients with Recurrent Glioblastoma Treated with PVSRIPO

Jun 22, 2018

Alexo Therapeutics Changes Name to ALX Oncology

Jun 20, 2018

AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial

Jun 19, 2018

7 Hills Pharma Launches With $2 Million SBIR Grant in Addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance

Jun 14, 2018

Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

Jun 14, 2018

AIVITA Biomedical Randomizes First Patient in Phase II Ovarian Cancer Trial

Jun 12, 2018

Aura Biosciences Earns CEO Cancer Gold Standard Accreditation

Jun 12, 2018

EpiVax Oncology Completes a $1.2M Bridge Financing

Jun 6, 2018

Peloton Therapeutics Initiates Phase 2 Trial of Oral HIF-2α Inhibitor PT2977 for Treatment of von Hippel-Lindau Disease-associated Kidney Cancer

Jun 4, 2018

Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

Jun 4, 2018

Portage provides update on its associate, Stimunity S.A, a Paris-based cancer immunotherapy company

Jun 4, 2018

MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients

Jun 4, 2018

Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting

Jun 4, 2018

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma

Jun 4, 2018

Ayala Pharmaceuticals Presents Phase 1b Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting for AL101, a Pan-Notch Inhibitor, in Patients with Locally Advanced or Metastatic Solid Tumors

Jun 4, 2018

Harbour BioMed and The Wistar Institute Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases

Jun 4, 2018

Results from Genelux Corporation's Phase 1b Trial of GL-ONC1 in Recurrent Ovarian Cancer to be presented at the ASCO Annual Meeting 2018

May 31, 2018

Bicycle Therapeutics and Cancer Research UK Announce Presentation at 2018 American Society of Clinical Oncology Meeting

May 30, 2018

Immunology and Cancer Research Leaders Join Elstar Therapeutics’ Scientific Advisory Board

May 30, 2018

NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

May 30, 2018

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

May 30, 2018

NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

May 29, 2018

NanOlogy™ to Unveil Positive Preclinical Data for Inhaled NanoPac® in Treatment of Lung Cancer at 2018 ASCO Annual Meeting

May 29, 2018

NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.

May 29, 2018

NanOlogy™ to Unveil Positive Preclinical Data for Inhaled NanoPac in Treatment of Lung Cancer at 2018 ASCO Annual Meeting

May 29, 2018

Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2018

Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer

May 24, 2018

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-Based Cancer Specific Immunotherapy (ECI-006) in Melanoma

May 18, 2018

Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins

May 18, 2018

Tarveda Therapeutics Presents Data Exploring the Efficacy of PEN-866 in Combination with PARP Inhibitors in Preclinical Models of Human Cancer at the AACR Annual Meeting 2018

May 18, 2018

Rgenix Presents Pre-Clinical Data on RGX-202 at the 2018 AACR Annual Meeting

May 17, 2018

Tarveda Therapeutics to Present Data from Phase 1 Study of PEN-221 at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

May 17, 2018

BioClin Therapeutics, Inc. Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 17, 2018

Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

May 17, 2018

Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma

May 16, 2018

PellePharm to Present Topical Patidegib and Skin Cancer Epidemiological Data at the 7th International Investigative Dermatology Meeting

May 16, 2018

MiNA Therapeutics to Present Initial Results from First-in-Human MTL-CEBPA Study at the 2018 ASCO Annual Meeting

May 16, 2018

Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

May 16, 2018

TARIS Presents Data Demonstrating Significant Local and Systemic Immune Modulation Following Continuous Low-Dose Bladder Delivery of Gemcitabine

May 16, 2018

HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders

May 15, 2018

MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 15, 2018

Celsius Therapeutics Launches with $65 Million in Series A Financing to Develop Precision Therapeutics for People with Autoimmune Diseases and Cancer

May 15, 2018

Agilvax Closes A1 Financing to Expand Pre-IND Studies for AX09 In Triple Negative Breast Cancer

May 14, 2018

Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

May 14, 2018

Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer

May 14, 2018

Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 12, 2018

FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy for Cancer Research Annual Meeting

May 12, 2018

Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

May 11, 2018

Evotec Forms Collaboration with Petra Pharma on Indigo Platform

May 11, 2018

ADC Therapeutics to Present Two New Investigational Antibody-Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting

May 11, 2018

Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer

May 10, 2018

FORMA Therapeutics Announces Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 10, 2018

Tango Therapeutics Bolsters Expertise in Oncology Translational Research and Clinical Pharmacology with Leadership Expansion

May 9, 2018

TARIS® Announces Late-Breaking Poster Presentation at American Association of Cancer Research Annual Meeting

May 3, 2018

Bicycle Therapeutics to Present New BT1718 Data in the "New Drugs on the Horizon" Session at the 2018 American Association for Cancer Research Meeting

May 3, 2018

U.S. FDA Grants Fast Track Designation to TARIS® for TAR-200 (GemRIS™) in Muscle Invasive Bladder Cancer

May 2, 2018

Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer

May 2, 2018

Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy

May 2, 2018

Merck KGaA, Darmstadt, Germany to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group

Apr 27, 2018

PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

Apr 17, 2018

BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types

Apr 16, 2018

Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago

Apr 12, 2018

Ascentage Pharma Announces Five Abstracts To Be Presented at the 2018 American Association for Cancer Research Annual Meeting

Apr 12, 2018

Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 Annual Meeting of the American Association for Cancer Research

Apr 10, 2018

Asana BioSciences Announces Presentations of ASN003 (BRAF/PI3K inhibitor) and ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting

Apr 9, 2018

GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018

Apr 9, 2018

TARIS Announces Late-Breaking Poster Presentation at American Association of Cancer Research Annual Meeting

Apr 4, 2018

BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer

Apr 3, 2018

U.S. FDA Grants Fast Track Designation to TARIS for TAR-200 (GemRIS™) in Muscle Invasive Bladder Cancer

Mar 28, 2018

Checkmate Pharmaceuticals to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Mar 28, 2018

Tempest Therapeutics Closes $70 Million Series B Financing

Mar 26, 2018

C4 Therapeutics Announces Publication in Nature Chemical Biology on Degradation Technologies Licensed from Dana-Farber Cancer Institute

Mar 26, 2018

Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia

Mar 26, 2018

Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 -- a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions -- in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy

Mar 23, 2018

First Alpha Tau Medical Summit Gathers Over 200 Oncologists and Physicians From All Around the World

Mar 22, 2018

Kineta Immuno-Oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference

Mar 19, 2018

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

Mar 15, 2018

Oncorus®, Inc., Presents Preclinical Data on Next-Generation Oncolytic Virus Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting

Mar 14, 2018

Atreca to Present at 2018 American Association for Cancer Research Annual Meeting

Mar 14, 2018

TARIS® Announces Research Collaboration Focused on Natural History of Muscle Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy

Mar 14, 2018

TARIS® Initiates Dosing of TAR-200 (GemRIS™) in Muscle-Invasive Bladder Cancer Patients Unfit for Curative Intent Therapy

Mar 14, 2018

TARIS Announces Research Collaboration Focused on Natural History of Muscle Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy

Mar 14, 2018

TARIS Initiates Dosing of TAR-200 (GemRIS™) in Muscle-Invasive Bladder Cancer Patients Unfit for Curative Intent Therapy

Mar 13, 2018

IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG

Mar 13, 2018

CrownBio Enters Strategic Partnership with Phanes Therapeutics to Accelerate Discovery and Development of Phanes’ Novel Oncology Agents

Mar 12, 2018

IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

Mar 9, 2018

MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease

Mar 8, 2018

Tango Therapeutics Expands Board of Directors with the Addition of Leading Oncology Experts with Deep Experience in Targeted and Personalized Therapies

Feb 26, 2018

The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Pancreatic Cancer Treatment

Feb 26, 2018

EpimAb Biotherapeutics Appoints Industry Veteran Bin Peng as Chief Medical Officer

Feb 22, 2018

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Metastatic Triple Negative Breast Cancer

Feb 21, 2018

Ascentage Pharma to Present at the IASLC 18th Lung Cancer Targeted Therapies Meeting

Feb 20, 2018

Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics

Feb 14, 2018

Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies

Feb 14, 2018

IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3

Feb 13, 2018

Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle®)

Feb 13, 2018

Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle)

Feb 6, 2018

Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA (pembrolizumab)

Feb 5, 2018

NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference

Feb 5, 2018

Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial

Feb 4, 2018

“‘Someday’ is Now!”: Anpac Bio and Med Partners Celebrate ‘National Cancer Prevention Month’ Surpassing 60,000 ‘Liquid Biopsy’ Cases

Feb 1, 2018

Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-in-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer

Feb 1, 2018

PharmAbcine Enters Collaboration with MSD Focused on Clinical Evaluation of TTAC-0001 in Combination with KEYTRUDA (pembrolizumab) in Recurrent Glioblastoma and Breast Cancer

Jan 30, 2018

BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

Jan 30, 2018

Skin Biology Receives US Patent for Non-toxic Skin Cancer Therapy With Copper Peptides

Jan 24, 2018

Treos Bio Announces FDA Approval of IND of Its First PolyPEPI™ Precision Cancer Vaccine for Metastatic Colorectal Cancer

Jan 23, 2018

Skyhawk Therapeutics Launches With $8 Million in Seed Financing to Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression

Jan 23, 2018

Tmunity Therapeutics Raises $100 Million in Series A Financing to Advance Portfolio of Next-Generation T cell Immunotherapies to Transform the Treatment of Cancer

Jan 22, 2018

BERG Announces FDA Orphan-Drug Designation of BPM31510 for the Treatment of Pancreatic Cancer

Jan 16, 2018

Context Therapeutics Announces the Acquisition of Apristor™ (Onapristone XR), an Investigational Phase 2 Drug for Metastatic Breast Cancer

Jan 16, 2018

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018

Jan 8, 2018

NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board

Jan 7, 2018

F1 Oncology Announces Development Milestone and $10M Equity Investment

Jan 4, 2018

Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Jan 4, 2018

Bluefield Innovations Pursues Broadly Applicable Cancer Target

Jan 2, 2018

NanOlogy™ to Present Update on Cancer Treatment Clinical Program at Biotech Showcase in San Francisco

Dec 20, 2017

Peloton Therapeutics Phase 1 Study of PT2385 Published in the Journal of Clinical Oncology Validates HIF-2α Antagonism for the Treatment of Kidney Cancer

Dec 20, 2017

AIVITA Biomedical Announces First Patient Enrolled in Phase II Clinical Trial for Late-Stage Ovarian Cancer

Dec 19, 2017

Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek

Dec 18, 2017

NanOlogy™ Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac® Adding to Trials in Prostate and Ovarian Cancers

Dec 18, 2017

NanOlogy™ Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers

Dec 14, 2017

Relay Therapeutics Secures $63 Million in Series B Financing

Dec 14, 2017

Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

Dec 14, 2017

Aura Biosciences Announces Publication of Preclinical Data Supporting AU-011’s Potent and Selective Anti-cancer Activity in Ocular Melanoma Tumors

Dec 14, 2017

Complix Receives €0.5 Million Grant to Further Develop its Pipeline of Proprietary Cell Penetrating Alphabodies™ Against Intracellular Cancer Targets

Dec 12, 2017

Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer

Dec 12, 2017

American Gene Technologies Receives U.S. Patent on Novel Immuno-Oncology Methods of Treating Cancer through Activation of Gamma Delta T Cells

Dec 11, 2017

OncoTartis Closes $6M Financing Round

Dec 6, 2017

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Dec 6, 2017

Bicycle Therapeutics and Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards

Dec 6, 2017

Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

Dec 5, 2017

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting

Dec 5, 2017

New Scientific Publication Supports Agilvax’s Novel Immunotherapy Development for Metastatic Breast Cancer

Nov 29, 2017

Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen

Nov 29, 2017

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy

Nov 29, 2017

Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business and Healthcare Acumen

Nov 28, 2017

Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement

Nov 21, 2017

Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

Nov 16, 2017

Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer

Nov 15, 2017

ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement

Nov 15, 2017

ITM’s Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a.177Lu-Edotreotide (Solucin) in Cancer Patients with GEP-NET

Nov 15, 2017

EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA (tivozanib)

Nov 14, 2017

Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit

Nov 14, 2017

Monopar Therapeutics, Inc. Announces Acquisition of GPX-150, a Broad Spectrum Phase II Cancer Drug Candidate, Closing on $9.7M in Financing, and Filing of Form 10 Registration Statement

Nov 14, 2017

OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)

Nov 13, 2017

NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model

Nov 13, 2017

DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting

Nov 10, 2017

IRX Therapeutics Announces Presentation of IRX-2 Phase 1b Biomarker Data in Early Stage Breast Cancer

Nov 8, 2017

Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Nov 7, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas

Nov 7, 2017

OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line Ovarian Cancer at the International Meeting of European Society of Gynaecological Oncology (ESGO) 2017

Nov 7, 2017

OncoResponse Adds Anti-EMP2 Antibody to Oncology Pipeline Through Acquisition of Paganini Biopharma

Nov 7, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac for Treatment of Mucinous Cysts of the Pancreas

Nov 7, 2017

EOC Pharma Completed Series B Financing From Leading Global Investors

Nov 7, 2017

Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer

Nov 7, 2017

Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer

Nov 6, 2017

STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research

Nov 6, 2017

NousCom Raises €42 Million Series B Financing

Nov 6, 2017

AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma

Nov 1, 2017

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells

Oct 31, 2017

Vedantra Pharmaceuticals Extends Research Collaboration with Neon Therapeutics to Develop Novel Cancer Immunotherapies

Oct 31, 2017

Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 31, 2017

CORRECTING and REPLACING Siamab Therapeutics Presents New Preclinical Safety Data for ST1 Antibody Therapeutics Program at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 31, 2017

Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Oct 31, 2017

Sermonix Pharmaceuticals Announces Recent Closure of $4.2 Million Seed Preferred Equity Bridge to Fund Operations, Prepare for Phase II Breast Cancer Study

Oct 30, 2017

Alpha Tau Medical Initiates First Clinical Trial in Italy to Treat Cancer with Alpha Radiation

Oct 30, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics

Oct 29, 2017

Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients

Oct 27, 2017

ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology

Oct 26, 2017

Bicycle Therapeutics to Present Preclinical Data on Lead Molecule BT1718 at the AACR-NCI-EORTC International Cancer Conference

Oct 26, 2017

OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting

Oct 24, 2017

Asana BioSciences to Present Updates on its Oncology Development Pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2017

Tolero Pharmaceuticals Announces Preclinical Data Supporting Development of TP-1287 and TP-3654 for Myc-dependent Triple Negative Breast Cancer

Oct 18, 2017

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Oct 17, 2017

Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer Therapy

Oct 16, 2017

Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Esophageal Cancer

Oct 16, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

Oct 16, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

Oct 12, 2017

IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer

Oct 11, 2017

VLP Therapeutics Announces Phase 1 SBIR Grant Award from National Cancer Institute

Oct 11, 2017

CicloMed Announces FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder Cancer

Oct 10, 2017

AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology

Oct 9, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Ovarian Cancer

Oct 9, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac for Ovarian Cancer

Oct 5, 2017

REVOLUTION Medicines Appoints Vincent Miller, M.D. to Board of Directors

Oct 5, 2017

WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

Oct 5, 2017

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

Oct 5, 2017

Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 5, 2017

Tolero Pharmaceuticals to Deliver Keynote Presentations at the 9th International Conference on Leukemia and Hematologic Oncology

Oct 4, 2017

Palleon Pharmaceuticals Raises $47.6 Million to Develop Glycoimmune Checkpoint Inhibitors, a New Class of Medicines Designed to Overcome Resistance to First-Generation Immuno-Oncology Drugs

Oct 4, 2017

eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer

Oct 4, 2017

Siamab Therapeutics and Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration to Develop Antibody Therapeutics Targeting Multiple Solid Tumors

Oct 3, 2017

Cullinan Oncology Secures $150 Million Series A Financing to Build Innovative Development Company

Oct 3, 2017

Vium Awards Grant to OncoSynergy to Further Preclinical Research in Ovarian Cancer Model

Oct 3, 2017

Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models

Sep 29, 2017

National Cancer Institute Awards Grant to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer

Sep 29, 2017

Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference

Sep 26, 2017

Glythera Licenses Novel Payload Class from Cancer Research UK for the Development of Next-Generation Antibody Drug Conjugates

Sep 25, 2017

EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology Deutschland - Deutsch USA - English España - español

Sep 21, 2017

FLX Bio Selects Immuno-Oncology Clinical Candidate

Sep 20, 2017

Treos Bio Enters into Agreement with PPD to Manage First-in-Man Trial of Its Lead Therapeutic Cancer Vaccine Program

Sep 20, 2017

AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in

Sep 19, 2017

BERG Broadens Relationship With The Department Of Defense (DoD) Center For Prostate Disease Research With New Predictive Biomarker Test For Prostate Cancer

Sep 19, 2017

Petra Pharma and Schrödinger Announce Research Collaboration

Sep 18, 2017

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Sep 18, 2017

FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

Sep 18, 2017

Formula Pharmaceuticals Announces Initiation of the First Clinical Trial for Allogeneic CIK-CAR Cancer Immunotherapy

Sep 14, 2017

Avelas Biosciences' AVB-620 Shows Sensitive In Vivo Visualization of Breast Cancer in Journal Publication

Sep 13, 2017

CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

Sep 13, 2017

Eos Biosciences Announces Issuance of U.S. Patent for Novel Oncology Theranostic

Sep 13, 2017

AVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridge

Sep 12, 2017

DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses

Sep 11, 2017

Lycera Presents Encouraging Safety Results from Phase 1 ARGON Study of LYC-55716 at the European Society for Medical Oncology (ESMO) Congress

Sep 11, 2017

Symphogen A/S: Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

Sep 11, 2017

BERG Presents Key Clinical Data at ESMO 2017 on BPM 31510 for Advanced Pancreatic Cancer Patients and BPM 31543 for Preventing Hair-Loss in Patients Treated With Chemotherapy

Sep 11, 2017

Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress

Sep 11, 2017

IRX Therapeutics Presents Positive IRX-2 Phase 2a Head and Neck Squamous Cell Carcinoma Clinical Results at the European Society for Medical Oncology Annual Congress 2017

Sep 8, 2017

Rafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting

Sep 6, 2017

Bexion Pharmaceuticals and CTI Clinical Trial and Consulting Services Announce Completion of First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

Sep 5, 2017

EnGeneIC Announces Publication in The Lancet Oncology of First Clinical Study Employing EDV™ Nanocell Platform to Enable microRNA Replacement Therapy

Aug 31, 2017

Tactiva Therapeutics to Present Positive Data on Novel Dual CD4/CD8 T Cell Receptor in Preclinical Models of Cancer at BioCentury's 24th Annual Newsmakers Conference

Aug 28, 2017

CBT Pharmaceuticals Appoints Nationally Recognized Leaders in Oncology to Newly Established Scientific Advisory Board

Aug 28, 2017

Gliknik Announces Dosing Of First Patient In Phase 2 Trial Targeting Prevention Of Recurrence Of High-Risk Oral Cavity Cancer

Aug 17, 2017

Atreca Completes Oversubscribed $35 Million Series B Financing to Advance Novel Cancer Immunotherapies

Aug 9, 2017

CureLab Oncology publishes proof of concept demonstrating that its product can reduce metabolic disorders induced by excessive food consumption.

Aug 3, 2017

Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Aug 3, 2017

Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity

Aug 3, 2017

EpiVax Awarded "Innovation Voucher" to Accelerate the Development of a Game Changing Cancer Therapy

Aug 2, 2017

Aprea Therapeutics Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Platinum-Resistant High-Grade Serous Ovarian Cancer

Aug 2, 2017

IRX Therapeutics to Present IRX-2 Clinical and Biomarker Updates at Upcoming Medical Conferences

Aug 2, 2017

Madison Vaccines Announces First Patient Dosed in an Expanded Combination Trial of MVI-816 Plus Keytruda for Metastatic, Treatment-Resistant Prostate Cancer

Jul 31, 2017

Immunomic Therapeutics Welcomes New Oncology Advisor

Jul 27, 2017

Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies

Jul 26, 2017

First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol in Recurrent Ovarian Cancer

Jul 25, 2017

Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration

Jul 24, 2017

Xcovery Collaborates with the National Cancer Institute and Children’s Oncology Group for The NCI-COG Pediatric MATCH Clinical Trial

Jul 20, 2017

CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies

Jul 19, 2017

Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

Jul 19, 2017

Aspyrian Therapeutics, Inc. closes $15.1M as part of a Series B-1 financing to support the advancement of its proprietary precision targeted therapy, RM-1929, to late stage clinical development and the progression of new proprietary immune oncology assets into the clinic.

Jul 18, 2017

PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology

Jul 17, 2017

Apexigen, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

Jul 17, 2017

Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer

Jul 12, 2017

Qu Biologics invited to present at US National Cancer Institute (NCI) Conference

Jul 11, 2017

Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals Inc and Advaxis Inc, Says a New Research Report at RnRMarketResearch.com USA - English USA - English

Jul 10, 2017

Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals Inc and Advaxis Inc, Says a New Research Report at RnRMarketResearch.com

Jul 3, 2017

Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline

Jun 30, 2017

eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy into First Oncology Clinical Studies

Jun 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics

Jun 22, 2017

Repare Therapeutics Raises US$68 Million Series A

Jun 20, 2017

Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and Gene Therapy Catapult

Jun 20, 2017

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer

Jun 20, 2017

Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer

Jun 19, 2017

Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement

Jun 14, 2017

Orum Therapeutics Raises $8 Million Series A Financing to Advance Cell-Penetrating Antibody Technology for Novel Cancer Therapeutics

Jun 12, 2017

Immunomic Therapeutics, Inc. to Participate in Webcast on Making a Name in Cancer Immunotherapy

Jun 12, 2017

Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer

Jun 12, 2017

Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients

Jun 7, 2017

Eureka Therapeutics and City of Hope Announce Agreement to Conduct Phase 1 Clinical Trial of Investigational ET1402L1 CAR-T Therapy in Liver Cancer

Jun 5, 2017

Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic "Universal Donor" CAR-T Cells at American Society of Clinical Oncology Annual Meeting

May 31, 2017

Atreca, Inc., and Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy R&D Collaboration

May 31, 2017

EpimAb Biotherapeutics Collaborates with WuXi Biologics to Advance Lead Bispecific Antibody Candidate towards Clinical Development

May 31, 2017

Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2017

Atreca, Inc., and Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy RandD Collaboration

May 24, 2017

OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2017

OncoQuest presenta los resultados clínicos internos de fase II de Oregovomab para el tratamiento de primera línea del cáncer de ovario en el congreso anual de la American Society of Clinical Oncology (ASCO)

May 23, 2017

Dragonfly Therapeutics Adds Natural Killer Cell-Based Cancer Immunotherapy Expert to Its Scientific Advisory Board

May 23, 2017

IVY and Immunomic Therapeutics to Host Cancer Moonshot Discussion

May 23, 2017

Dragonfly Therapeutics Adds Natural Killer Cell-Based Cancer Immunotherapy Expert to Its Scientific Advisory Board France - Français España - español USA - English Deutschland - Deutsch

May 21, 2017

Immunomic Therapeutics Announces Winner of Cancer Discovery Incubator Award

May 18, 2017

Cortice Biosciences Announces an Upcoming Presentation at the 2017 American Society of Clinical Oncology Annual Meeting

May 18, 2017

SIWA Therapeutics Takes a Key Step Forward in Novel Efforts to Treat Cancer by Removing Senescent Cells

May 15, 2017

Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)

May 15, 2017

Tactiva Therapeutics Presents Positive Data on Novel Dual CD4/CD8 T Cell Receptor in Preclinical Models of Cancer

May 13, 2017

FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain Cancer

May 11, 2017

Peloton Therapeutics Initiates Patient Dosing in Phase 2 Study of PT2385 for von Hippel-Lindau Disease-Associated Kidney Cancer

May 11, 2017

DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer

May 10, 2017

Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs

May 9, 2017

OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

May 6, 2017

Immune-Onc Therapeutics, Inc. Announces Partnership with University of Texas to Develop Novel Cancer Immunotherapy

May 6, 2017

Innocrin Pharmaceuticals Appoints Fred Eshelman, PharmD as CEO and is Granted Fast Track Designation by FDA for Seviteronel Treatment of Women with Triple-negative Breast Cancer and Women or Men with Estrogen Receptor-positive Breast Cancer

May 5, 2017

PIN Pharma to Present a Poster at AACR International Conference on Translational Cancer Medicine

May 4, 2017

amcure Presents Preclinical Data on Lead Cancer Compound AMC303 at AACR Annual Meeting

May 4, 2017

Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting

May 3, 2017

Bicycle Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

May 3, 2017

Treos Bio Announces Filing of Key Patent Applications on its Precision Therapeutic Cancer Vaccine Development Platform and its Compositions for Colorectal and Breast Cancers

Apr 14, 2017

Applied BioMath, LLC announces collaboration with Northern Biologics for semi-mechanistic PK/PD modeling in Oncology

Apr 6, 2017

Madison Vaccines Inc Says Prostate Cancer Expert Douglas McNeel, MD, PhD, Will Address the World Vaccine Congress about New Immunologic Approaches to Prostate Cancer

Apr 4, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017

Apr 3, 2017

BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel

Apr 3, 2017

AIVITA Biomedical CEO Hans Keirstead, Ph.D. to Present as Distinguished Speaker at Upcoming Stem Cell Summit 2017

Mar 31, 2017

CORRECTING and REPLACING -- FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4

Mar 31, 2017

FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4

Mar 30, 2017

Antitumor Immunity Triggered by DNAtrix Armed Viruses to be Presented at the 2017 Annual Meeting of the American Association for Cancer Research

Mar 30, 2017

Samus Therapeutics Announces Launch of Expanded Clinical Development Programs for Novel Anti-Epichaperome Small Molecules to Diagnose and Treat Cancer and Neurodegenerative Disease

Mar 30, 2017

Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes

Mar 30, 2017

Panacea Pharmaceuticals, Inc. Presents Data on Targeted Killing of Leukemia Cells By Its Radiolabeled Monoclonal Antibody to the Cancer Biomarker HAAH

Mar 28, 2017

Immune-Onc Therapeutics, Inc. Announces Licensing and Collaboration With Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center to Develop Novel Cancer Immunotherapy

Mar 28, 2017

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting

Mar 27, 2017

Asana BioSciences Highlights Progress in Its Oncology Portfolio with New Data at AACR 2017 on ASN002 (SYK/JAK inhibitor), ASN003 (BRAF/PI3K inhibitor) and ASN004 (5T4-targeted antibody drug conjugate)

Mar 24, 2017

Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

Mar 23, 2017

CORRECTING and REPLACING Siamab Therapeutics to Present New Preclinical Data for its Novel Antibodies and Antibody-Drug Conjugates at the American Association for Cancer Research Annual Meeting 2017

Mar 22, 2017

Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center

Mar 22, 2017

Karolinska Development company Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center

Mar 21, 2017

Precision Therapeutic Cancer Vaccine Developer Treos Bio Opens U.S. Headquarters in San Francisco

Mar 21, 2017

Madison Vaccines Incorporated Expands Clinical Trial of MVI-118 for Prostate Cancer to University of Washington

Mar 20, 2017

REVOLUTION Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development

Mar 16, 2017

Cell Medica: £60 Million Series C Financing to Advance Multiple Cancer Programmes

Mar 14, 2017

twoXAR Announces Preclinical Proof-of-Concept Data on Novel Liver Cancer Candidate

Mar 14, 2017

Vedantra Pharmaceuticals Announces a Joint Research Collaboration with Neon Therapeutics to Develop Cancer Vaccines

Mar 13, 2017

Distinguished Cancer Physician-Scientist Dr. Herbert (Bob) Pinedo joins Amunix Scientific Advisory Board

Mar 8, 2017

Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn

Feb 27, 2017

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer

Feb 24, 2017

Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy

Feb 23, 2017

Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments

Feb 23, 2017

Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA (pembrolizumab)

Feb 23, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium

Feb 22, 2017

Atreca, Inc. Presents New Preclinical Findings for Novel Cancer Immunotherapy Platform at Molecular Medicine Tri-Conference 2017

Feb 22, 2017

PMV Pharma Secures $74 Million in Series B Financing for Cancer Drugs Targeting p53

Feb 21, 2017

Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation

Jan 23, 2017

Hope Biosciences Licenses nuc-Gemcitabine, A 'Trojan Horse' Anti-nucleolin-Gemcitabine Aptamer Drug Conjugate Against Cancer

Jan 19, 2017

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec nanotech platform

Jan 17, 2017

Xcovery Joins National Cancer Institute (NCI) Formulary to Help Expedite Cancer Clinical Trials

Jan 17, 2017

Panacea Pharmaceuticals Initiates Phase I Study of First-in-Class Cancer Vaccine Therapy Candidate in Patients with Persistent Prostate Cancer

Jan 9, 2017

Atreca, Inc. to Present Cancer Immunotherapy Platform and Data at the PepTalk 2017 Conference

Jan 6, 2017

Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic

Jan 6, 2017

TARIS Biomedical® Announces Positive Results from Ph1b Trial of TAR-200 (GemRISTM) in Patients with Muscle Invasive Bladder Cancer

Jan 6, 2017

BioAtla and F1 Oncology Announce Global Collaboration to Develop Adoptive Cellular Therapies for Solid Tumors

Jan 6, 2017

TARIS Biomedical Announces Positive Results from Ph1b Trial of TAR-200 (GemRISTM) in Patients with Muscle Invasive Bladder Cancer

Jan 5, 2017

Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2017

Jan 4, 2017

Tarveda Therapeutics Announces Phase 1/2a Clinical Trial of PEN-221 Underway in Patients with Neuroendocrine Tumors and Small Cell Lung Cancer

Dec 15, 2016

Cancer Research UK and Bicycle Therapeutics Collaborate to Trial New Therapy for Advanced Solid Tumours

Dec 14, 2016

amcure Raises €6 Million in Series B Financing and Expands Advisory Board

Dec 14, 2016

Ability Pharmaceuticals Announces Orphan Drug Designation in the US for ABTL0812 in Pancreatic Cancer

Dec 13, 2016

REVOLUTION Medicines Names Distinguished Cancer Scientists and Drug Hunters to Senior Advisory Roles

Dec 13, 2016

Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium

Dec 12, 2016

Atreca Announces Lead Preclinical Projects in Cancer Immunotherapy and Additional Disease Indications

Dec 12, 2016

Accelerator Corporation Announces $7M Series A Investment in ApoGen Biotechnologies to Develop a New Class of Drugs Targeting Resistance to Cancer Therapy

Dec 7, 2016

OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

Dec 7, 2016

Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene for Breast Cancer Treatment

Dec 6, 2016

Alopexx Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society Of Hematology Annual Meeting

Dec 6, 2016

ENYO Pharma Receives a €2.5 Million Grant from EU under the Horizon2020/SME Instrument Phase 2 Programme for Its Project MIMESIS

Dec 5, 2016

Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer

Nov 29, 2016

Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Nov 29, 2016

OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

Nov 28, 2016

Bicycle Therapeutics to Present Preclinical Data at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Nov 28, 2016

Sermonix Pharmaceuticals to Present Poster on Physician Perceptions of Menopausal SERMs at San Antonio Breast Cancer Symposium

Nov 28, 2016

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Triple Negative Breast Cancer

Nov 28, 2016

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Smoldering Multiple Myeloma and Upcoming Presentation of Positive Results from Phase 1/2a Clinical Trial at ASH

Nov 22, 2016

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First-Line Therapy in Patients with Endometrial or Squamous Lung Cancer

Nov 22, 2016

Research and Markets - Global Cancer Vaccines Market Worth USD 3.4 Billion by 2021 - Analysis, Technologies and Forecasts Report 2016-2021 - Vendors: Advaxis, Curevac, Sotio

Nov 11, 2016

Atreca Presents Promising Findings from Lead Antibody Program at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 11, 2016

Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of Its Phase 2 Cancer Immunotherapy, Imprime PGG

Nov 10, 2016

Cell Medica and Baylor College of Medicine Expand Partnership to Develop Allogeneic CAR-NKT Cells for Cancer Treatment

Nov 8, 2016

Immunomic Therapeutics Gives Back to Maryland Biotech Community

Nov 8, 2016

Madison Vaccines Says Promising Early Data on the Combination of Its Lead Prostate Cancer Vaccine with a PD-1 Inhibitor Will Be Presented at Major Medical Meeting Nov. 11th

Oct 31, 2016

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept

Oct 27, 2016

Madison Vaccines Incorporated Says Its Investigational New Prostate Cancer Treatment is Available for the First Time in New Jersey Through a Clinical Trial at Rutgers Cancer Institute of New Jersey

Oct 24, 2016

BERG Expands Research Collaboration with Department of Defense and Walter Reed National Military Medical Center to Advance Precision Medicine for Breast Cancer Patients

Oct 24, 2016

ApeX Therapeutics Changes Name to Apexian Pharmaceuticals to Reflect Broader Advancement of Oncology Pipeline

Oct 11, 2016

Bicycle Therapeutics Appoints Peter U. Park, Ph.D., as Vice President of Oncology Research

Oct 10, 2016

Aprea Therapeutics Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with APR-246 in Presentation at 2016 European Society for Medical Oncology (ESMO) Annual Meeting

Oct 10, 2016

Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib trial of APR-246 in ovarian cancer.

Oct 10, 2016

Aprea Therapeutics Announces First Patients Enrolled in Phase II Clinical Study of APR-246 for the Treatment of High-Grade Serous Ovarian Cancer

Oct 10, 2016

Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer

Oct 9, 2016

EnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology

Oct 5, 2016

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

Oct 5, 2016

Innocrin Pharmaceuticals, Inc. Appoints Edwina Baskin-Bey, MD as Chief Medical Officer and Expands the Ongoing Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer (TNBC)

Oct 4, 2016

Evotec and Carrick Therapeutics Build Strategic Alliance

Oct 4, 2016

Immunomic Therapeutics (ITI) and Nature Technology Corporation (NTC) Jointly Announce Expanded Agreement

Oct 4, 2016

Asana BioSciences Announces Acceptance of Its Third IND Application in Oncology

Oct 3, 2016

Launch of Carrick Therapeutics Signals New Approach to Cancer Therapies

Sep 21, 2016

Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies

Sep 20, 2016

Live Like Bella® & Biomarck Pharmaceuticals launch partnership to offer innovative inhaled medication to children battling cancer

Sep 20, 2016

Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute

Sep 19, 2016

Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

Sep 19, 2016

PIN Pharma to Present a Poster at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sep 13, 2016

Siamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium

Sep 8, 2016

twoXAR Sets Sights on Liver Cancer With New Collaboration

Sep 6, 2016

Peloton Therapeutics, Inc. Announces Dual Publications of HIF-2α Antagonism in Kidney Cancer in the Journal Nature

Aug 29, 2016

CBT Pharmaceuticals Closes $9.75 Million Series A Financing Led by OrbiMed for Development of Oncology Pipeline

Aug 24, 2016

Cell Medica and UCL Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer

Aug 24, 2016

Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications

Aug 23, 2016

Immix Biopharma, Inc. accelerates financing efforts to extend its cancer therapeutic platform after receiving positive stability data for lead candidate

Aug 11, 2016

Vedanta Biosciences Announces Collaboration with the NYU Langone Medical Center to Develop Microbiome-Derived Immunotherapies for Cancer

Aug 11, 2016

Global Non-Small Cell Lung Cancer Pipeline Review, H1 2016 - Analysis, Technologies and Forecasts Report - Key Vendors: 4SC, AbbVie, HitGen - Research and Markets

Aug 10, 2016

TARIS Biomedical Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Bladder Cancer

Aug 4, 2016

Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets

Aug 3, 2016

Sermonix Pharmaceuticals Convenes Breast Cancer Oncology Steering Committee to Explore Utility of Lasofoxifene

Jul 18, 2016

Bexion Pharmaceuticals Receives FDA Clearance for the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer

Jul 13, 2016

TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer

Jul 13, 2016

TARIS Biomedical Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer

Jun 29, 2016

Xcovery Announces Initiation of Phase 3 Trial of X-396 in ALK+ Non-Small Cell Lung Cancer

Jun 29, 2016

Cyteir Therapeutics Receives $2M Grant from National Cancer Institute

Jun 22, 2016

Atreca Appoints Leading Cancer Clinical Researcher Lawrence Fong, M.D., as a Technical Advisor

Jun 22, 2016

IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth

Jun 21, 2016

AiVita Biomedical Receives FDA Approval for Phase II Ovarian Cancer Treatment

Jun 17, 2016

Cell Medica and Baylor College of Medicine Announce Exclusive Licensing Agreement and Co-Development Partnership to Create Next Generation Cellular Immunotherapy Products for the Treatment of Cancer

Jun 17, 2016

Orbus Therapeutics Granted Orphan Drug Designation by European Medicines Agency for Late-Stage Brain Cancer Drug

Jun 15, 2016

Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics

Jun 6, 2016

Peloton Therapeutics, Inc. Presents Clinical Data on First-in-Class Oral HIF-2α Inhibitor in Patients with Advanced Kidney Cancer at 2016 ASCO Annual Meeting

Jun 5, 2016

BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting

Jun 3, 2016

Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the Annual Meeting of the American Society of Clinical Oncology

Jun 2, 2016

MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer

Jun 2, 2016

Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents

May 31, 2016

Blaze Bioscience Announces Trial in Progress Presentation at ASCO 2016 Annual Meeting

May 26, 2016

Caladrius Biosciences Licenses Cell Therapy Technology for Ovarian Cancer and Subleases Irvine Facility to AiVita Biomedical

May 20, 2016

Xcovery Presents Data Supporting the Potential Efficacy of X-396 in Patients with ALK+ Non-Small Cell Lung Cancer at the AACR Annual Meeting 2016

May 19, 2016

Abpro Announces Agreements with Two Boston Hospitals to Co-develop Therapeutics for Inflammation, Autoimmunity, Fibrosis and Oncology

May 14, 2016

Parker Institute for Cancer Immunotherapy and PsiOxus Therapeutics Announce Intention to Collaborate on Tumor-Specific Immuno-Gene Therapy

May 12, 2016

Innocrin Pharmaceuticals, Inc. Begins Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer and Expands Two Phase 2 Studies of Seviteronel in Men with Metastatic Castrate-resistant Prostate Cancer

May 9, 2016

Avelas Biosciences Announces Positive Interim Phase 1b Results and Advances to Dose Expansion Stage

May 2, 2016

Atreca Expands Leadership Team, Appoints Accomplished Cancer Immunotherapy Researcher and Drug Developer Norman M. Greenberg, Ph.D., as Chief Scientific Officer

May 2, 2016

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

May 2, 2016

SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer

Apr 27, 2016

BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer

Apr 19, 2016

Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting

Apr 19, 2016

Breakthrough Achieved by Antikor Biopharma with Fragment-Drug Conjugates

Apr 18, 2016

Immunomic Therapeutics (ITI) Featured at Maryland Regional Biotech Forum

Apr 18, 2016

BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting

Apr 18, 2016

Triphase Accelerator Corporation Announces Positive Preclinical Results for CBZed-Nano™ in Docetaxel-Resistant Prostate Cancer Models

Apr 14, 2016

Asana BioSciences, LLC to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting

Apr 13, 2016

Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences

Apr 12, 2016

EUSA Pharma Announces Acquisition of Global Rights to Next Generation Oncology Supportive Care Product Arcoral Tab from Arcoral Pharma

Apr 11, 2016

Results from Five Oncology Collaborations to Showcase RareCyte CTC Liquid Tissue Biopsy Technology at AACR Annual Meeting 2016

Apr 7, 2016

EnGeneIC Announces Publication of Late-Stage Canine Brain Cancer Study Results in PLOS ONE

Apr 5, 2016

SELLAS Life Sciences Group Receives a Favorable Opinion for European Orphan Drug Designations for WT1 Cancer Vaccine (galinpepimut-S) for the Treatment of Acute Myeloid Leukemia and for Malignant Pleural Mesothelioma

Apr 4, 2016

Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis

Apr 4, 2016

Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing

Mar 29, 2016

Immunomic Therapeutics (ITI) and Lysosomal Associated Membrane Protein (LAMP) Based Nucleic Acid Immunotherapy Featured At 2016 World Vaccine Congress

Mar 29, 2016

Gadeta Closes EUR 7 Million Series A Financing to Advance Novel Cancer Immunotherapies to the Clinic

Mar 22, 2016

Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

Mar 21, 2016

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

Mar 18, 2016

eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting

Mar 11, 2016

Atreca Announces Presentation of Preclinical Data for Cancer Immunotherapy Program

Mar 10, 2016

PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study

Mar 10, 2016

ImmunoMet Therapeutics Announces the Formation of Scientific Advisory Board

Mar 10, 2016

Aspyrian Therapeutics Inc. closes a $40M Series B financing to advance the precision targeted cancer therapy, RM-1929, to late stage clinical development in recurrent head and neck cancer and other cancer areas.

Mar 8, 2016

ImmunoMet Therapeutics Raises $5.2 million in a Series A Financing

Feb 22, 2016

Formula Pharmaceuticals and Rockland Immunochemicals Enter Into a Collaboration To Develop C.I.K. CAR Immunotherapy Pipeline for the Treatment of Cancer

Feb 8, 2016

Crescendo Biologics Presents Key Oncology Data on Humabody™ Drug Conjugates

Jan 27, 2016

Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer

Jan 19, 2016

IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR

Jan 12, 2016

FORMA Therapeutics and Cancer Research Technology Form a Third Virtual Company to Advance Deubiquitination Assets

Jan 11, 2016

Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis

Jan 8, 2016

Xcovery Announces Updated Clinical Data on X-396 in Patients with ALK+ Non-Small Cell Lung Cancer at the 4th AACR-IASLC International Joint Conference

Jan 7, 2016

PsiOxus Therapeutics Appoints Dr Paolo Paoletti as Chairman of the Board

Jan 7, 2016

Eureka Therapeutics Announces Exclusive License Agreement between Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Use of a Novel, Fully-Human MUC16 Binder in CAR T Cell Immunotherapy

Jan 7, 2016

C4 Therapeutics Launches with $73 Million Series A Financing

Jan 6, 2016

Innocrin Pharmaceuticals, Inc. Granted Fast Track Designation by FDA for VT-464 Treatment of Patients with Metastatic Castrate-resistant Prostate Cancer

Jan 6, 2016

Complix Enters into Strategic Collaboration with MSD to Develop Cell-Penetrating Alphabodies to Treat Cancer

Jan 5, 2016

Xcovery to Present X-396 in ALK+ Non-Small Cell Lung Cancer Study Data at 4th Annual AACR-IASLC International Joint Conference

Jan 4, 2016

Asana BioSciences Appoints Dr. Kapil Dhingra to its Oncology Scientific Advisory Board

Dec 21, 2015

ExCellThera Announces Initiation of Clinical Trial for Cancer Patients

Dec 21, 2015

Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer

Dec 10, 2015

Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center

Dec 8, 2015

Panacea Pharmaceuticals closes its Series E financing for a total of $15 million to fund the Phase 1 clinical study of its lead cancer immunotherapeutic drug and pursue its late stage pre-clinical candidates toward integrated cancer management

Dec 7, 2015

Alopexx Oncology Presents Encouraging Phase I/II Clinical Data On DI-Leu16-IL2 At The American Society Of Hematology Annual Meeting

Dec 2, 2015

ORIC Pharmaceuticals Announces $53 Million Series B Financing to Support Discovery and Development of Novel Therapies for Treatment-Resistant Cancers

Nov 20, 2015

Cortice Biosciences Announces Updated Results From Clinical Trials Evaluating TPI 287 for Treatment of Brain Malignancies

Nov 19, 2015

Cavion to Deliver Three Presentations at SNO, the World’s Leading Multidisciplinary Brain Cancer Conference

Nov 18, 2015

Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer

Nov 17, 2015

Qu Biologics Granted Three New Patents for Treating Inflammatory Bowel Disease, Colon Cancer and Skin Cancer

Nov 9, 2015

Morphotek, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology

Nov 5, 2015

Intensity Therapeutics Preclinical Results Show Anti-Cancer Synergy of INT230-6 with Anti-PD-1 Compounds

Nov 4, 2015

Atreca, Inc., Completes Oversubscribed $56 Million Series A Funding to Advance Pipeline of Novel Cancer Immunotherapies

Nov 3, 2015

Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting

Nov 3, 2015

CureVac raises $110 Million in a private placement

Nov 3, 2015

Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound

Nov 2, 2015

Asana BioSciences to Present Pre-Clinical Data for a Novel Dual Inhibitor of B-Raf and PI3 Kinase Pathway at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 9, 2015

Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-vax platform to prevent and treat allergies

Oct 6, 2015

Oncoceutics Closes Series A Financing for First-in-Class Cancer Drug

Oct 1, 2015

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Sep 30, 2015

Aura Biosciences Forms Clinical Advisory Board in Ocular Oncology and Strengthens Clinical Team to Prepare for Clinical Development of Lead Program in Ocular Melanoma

Sep 21, 2015

Aura Biosciences Announces Publication Describing Selective Binding of Viral-like Particles to Cancer Cells

Sep 15, 2015

Madison Vaccines Says Clinical Trial Begins for Its 2nd Prostate Cancer Vaccine, MVI-118, Intended to Delay Disease Progression in Men with Metastatic Disease

Sep 8, 2015

National Institutes of Health to Evaluate Berg's Drug for the Treatment of Kidney Cancer

Sep 2, 2015

ADC Therapeutics Secures $80m Financing to Progress Its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

Aug 25, 2015

Chrono Therapeutics Receives Second Fast Track SBIR Grant from National Cancer Institute for Patient-individualized Smoking Cessation Therapy

Aug 19, 2015

Orbus Therapeutics Secures $32.5 Million Series A Financing to Advance Late-Stage Brain Cancer Drug

Aug 19, 2015

EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors

Aug 19, 2015

Madison Vaccines Announces Patient Dosing Underway in Clinical Trial Pairing Its Lead Prostate Cancer Vaccine, MVI-816, with PD1 Inhibitor Pembrolizumab

Aug 12, 2015

Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment for Development of Novel Immuno-Oncology Product Platform

Aug 10, 2015

Evotec, Apeiron Biologics and Sanofi Jointly Develop Novel Small Molecule-Based Cancer Immunotherapies

Jul 27, 2015

Aspyrian Therapeutics Inc. Closes $4.25M Series A Extension Financing to Support the Execution of Phase 1 Clinical Studies of the Precision Targeted Cancer Therapy, RM-1929, to Treat Late-Stage Recurrent Head and Neck Cancers

Jul 23, 2015

Cancer Prevention Pharmaceuticals, Inc. Announces Appointment of Jon S. Saxe to its Board of Directors

Jul 13, 2015

Monopar Therapeutics gibt Partnerschaft mit Cancer Research UK und Cancer Research Technology für die Entwicklung eines neuen Onkologie-Wirkstoffs bekannt

Jul 13, 2015

Monopar Therapeutics annonce un partenariat avec Cancer Research UK et Cancer Research Technology visant à développer un nouveau composé oncologique

Jul 13, 2015

Insilico Medicine, Inc. to Utilize Deep Learning for Drug Repurposing and Discovery in Cancer and Age-Related Diseases

Jul 9, 2015

Monopar Therapeutics Announces Partnership With Cancer Research UK And Cancer Research Technology To Develop New Oncology Compound

Jul 7, 2015

CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer

Jul 7, 2015

Blaze Bioscience’s BLZ-100 Receives Orphan Drug Designation from FDA for Brain Cancer

Jun 25, 2015

Invenra and Oxford BioTherapeutics Enter Collaboration to Discover Novel Therapeutic Antibodies Targeting Cancer

Jun 19, 2015

Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics' Novel Small-Molecule Approach to Cancer Treatment

Jun 15, 2015

Batu Biologics Reports Combination Therapy Boosts Results in Tumor Blood Vessel-Killing Strategy

Jun 9, 2015

Lycera and Celgene Announce an Exclusive Strategic Collaboration to Advance Novel Immune Modulators

Jun 4, 2015

Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Children with Brain Cancer

May 27, 2015

Innocrin Pharmaceuticals, Inc. Initiates Phase 2 Castration-Resistant Prostate Cancer (CRPC) Study in Men Who Have Failed Enzalutmaide or Abiraterone

May 19, 2015

PsiOxus Therapeutics Raises a £25M Series C Investment to Progress Oncolytic Virus Plus Checkpoint Inhibitor Combination Study in Metastatic Colorectal Cancer

May 19, 2015

Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer

May 16, 2015

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting

May 12, 2015

Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer

May 4, 2015

Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies

Apr 23, 2015

US Patent Granted for Batu Biologics Cancer Immunotherapeutic Product ImmXcyteTM

Apr 16, 2015

Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients

Apr 9, 2015

Cortice Biosciences Announces Upcoming Clinical Trial Presentation at the 15th Annual Meeting of the American Association for Cancer Research

Mar 24, 2015

Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's and Janssen's Criteria and Achieves Milestone Ahead of Schedule

Mar 23, 2015

FORMA Therapeutics and Cancer Research Technology Form Two Virtual Companies to Advance Deubiquitination Assets

Mar 19, 2015

Lycera to Present at the 2015 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2015

Madison Vaccines Announces Program Expansions for Its Investigational Prostate Cancer Vaccines

Feb 26, 2015

Innocrin Pharmaceuticals Inc. to Present Interim Results from Its Phase 1/2 Prostate Cancer Clinical Study and Preclinical Results That Demonstrate VT-464 Efficacy in a Clinically-Relevant Enzalutamide-Resistant Mouse Model

Feb 10, 2015

Panacea Pharmaceuticals Engages Accelovance For Clinical Development Of Its Novel Nanoparticle-Based Therapeutic Cancer Vaccine

Feb 4, 2015

Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer

Feb 4, 2015

Batu Biologics Appoints Dr. Santosh Kesari to Scientific Advisory Board

Jan 20, 2015

Qu Biologics Launches Phase 2a Clinical Trial for Non-small Cell Lung Cancer (NSCLC)

Jan 14, 2015

3SBio Signs Exclusive Patent License Agreement for DIG-KT, a Bi-Specific mAb targeting VEGFR2 and Tie-2 with PharmAbcine

Jan 13, 2015

Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis as Chairman of the Board

Jan 7, 2015

Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board

Jan 6, 2015

EnGeneIC Completes $10 Million Series B Financing Led by U.S. Institutional Investor

Jan 5, 2015

Lycera Scientists Identify Endogenous Agonists For RORgamma That Control Th17 Cell Differentiation

Dec 11, 2014

Batu Biologics Submits Investigational New Drug Application for Lung Cancer Anti-Angiogenic Immunotherapy with FDA

Nov 25, 2014

Cell Medica Announces £50 Million Series B Round to Advance Cancer Program

Nov 19, 2014

Batu Biologics Recruits Cancer Immunologist to Scientific Advisory Board

Nov 18, 2014

3SBio Signs Exclusive Patent License Agreement for Tanibirumab, an Anti-VEGFR2/KDR mAb with PharmAbcine

Nov 13, 2014

Innocrin Pharmaceuticals and the Prostate Cancer Foundation (PCF) Join Forces for Innovative Phase 2 Clinical Study

Nov 11, 2014

Batu Biologics Recruits Inventor of Licensed UCSD Cancer Immunotherapy to Scientific Advisory Board

Nov 7, 2014

Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity

Nov 3, 2014

QUE Oncology, Inc. Announces Positive Phase 1 Results with Q-122

Oct 31, 2014

Xcovery Presents Phase 1 Results of X-396 in ALK positive NSCLC at the 2014 Multidisciplinary Symposium in Thoracic Oncology

Oct 31, 2014

Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting

Oct 28, 2014

Raze Therapeutics Appoints Mikel Moyer, PhD, as Vice President, Molecular Discovery

Oct 28, 2014

Apogenix - Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research

Oct 22, 2014

Innocrin Pharmaceuticals Created as a Spin-out of the Prostate Cancer Program from Viamet Pharmaceuticals

Oct 16, 2014

Batu Biologics Awarded Exclusive License from University of California San Diego for Drug That Stimulates Immune System to Kill Cancer

Oct 14, 2014

Raze Therapeutics Launches with $24 Million Series A Financing to Advance a New Class of Oncology Therapeutics Targeting Metabolic Pathways Essential to Cancer Growth and Survival

Oct 14, 2014

Rigontec GmbH Raises €9.45m in a First Closing of a Series A Financing Round to Advance RNA-based Immunotherapeutics for Cancer and Viral Diseases

Oct 14, 2014

SELLAS Life Sciences Group Selects PPD As Its Strategic CRO Partner To Advance Zolpidem And WT1 Cancer Vaccine

Oct 9, 2014

Omniox, Inc. Receives Wellcome Trust Translation Fund Award

Oct 9, 2014

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference

Oct 7, 2014

Cavion and Yale University Announce First Patient Enrolled in Phase 1b Clinical Trial in Brain Cancer

Sep 23, 2014

Forma Therapeutics and Moffitt Cancer Center Establish Multiyear Epigenetics Alliance

Sep 18, 2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

Sep 16, 2014

Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine

Sep 16, 2014

Federal Cancer Research Funding Crisis Threatens Nation's Mortality Rate, Assert Top Cancer Researcher Patricia Berg, Ex-White House Spokesman Robert Weiner and Policy Analyst Tom Sherman

Sep 15, 2014

EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research

Sep 10, 2014

Avelas Biosciences Extends Series B Financing to $7.4 Million to Support Clinical Development of Real-Time Cancer Visualization Technology

Sep 4, 2014

GamaMabs Pharma Announces Two Scientific Communications on Its AMHR2 Project

Sep 4, 2014

SELLAS Life Sciences Group Signs Exclusive License Agreement for Global Rights on Development and Commercialization of WT1 Cancer Vaccine with Memorial Sloan Kettering Cancer Center

Aug 28, 2014

OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial

Aug 18, 2014

Batu Biologics Achieves Goal in Successful Crowdfunding Campaign

Aug 12, 2014

FORMA Therapeutics and Paradigm Announce Molecular Profiling Collaboration for Drug Candidates

Jul 27, 2014

Batu Biologics Strategy for FDA Approval of Lung Cancer Immunotherapy Featured in San Diego Business Journal

Jul 17, 2014

Batu Biologics’ Lung Cancer Immunotherapy Featured in CEOCFO Magazine

Jul 7, 2014

Batu Biologics Reaches 50% of Crowdfunding Goal

Jul 2, 2014

Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

Jul 2, 2014

Batu Biologics Appoints Biotechnology Industry Veteran, Dr. Alan Lewis, to Scientific Advisory Board

Jun 30, 2014

Batu Biologics Recruits Renowned Cancer Immunologist to Scientific Advisory Board

Jun 23, 2014

Madison Vaccines Incorporated Announces Expansion of a Phase 2 Clinical Trial for MVI-816, Its Lead DNA Vaccine for Prostate Cancer

Jun 17, 2014

PsiOxus Therapeutics Initiates ‘OCTAVE’ Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev

Jun 13, 2014

KalGene Pharmaceuticals, Sunnybrook Research Institute, Ontario Cancer Biomarker Network and CIMTEC announce multi-year collaboration to tackle aggressive cancers.

Jun 9, 2014

Batu Biologics Announces FDA Development Plans for ValloVax™ Angiogenesis-Targeting Cancer Vaccine

Jun 3, 2014

Xcovery Presents Interim Phase 1 Results of X-396 in ALK positive NSCLC at the American Society for Clinical Oncology Annual Meeting

May 30, 2014

PMV Pharmaceuticals Appoints Steven H. Holtzman to the Board of Directors

May 28, 2014

Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute

May 28, 2014

Research and Markets: Worldwide Uterine Cancer Pipeline Report 2014 featuring Azaya Therapeutics Incorporated, EndoCeutics and Sunshine Biopharma

May 27, 2014

DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer

May 23, 2014

Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax

May 19, 2014

Xcovery Announces Presentation at the 2014 American Society of Clinical Oncology Annual Meeting

May 18, 2014

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

May 13, 2014

PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients

May 9, 2014

Batu Biologics Files Patent Covering New Use of Approved Drug for Decreasing Cancer Immunotherapy Toxicity

May 5, 2014

FORMA Therapeutics Acquires Covalent Chemistry Platform from Netherlands Cancer Institute

Apr 29, 2014

Ambrx and Zhejiang Hisun Pharmaceutical to Collaborate on the Development and Commercialization of Bispecifics for Cancer

Mar 25, 2014

AvidBiotics Granted U.S. Patent for Novel Immunotherapeutic Platform

Mar 19, 2014

Argos Therapeutics to Present at Regenerative Medicine and Cancer Immunotherapy Meetings

Mar 17, 2014

Argos Therapeutics to Present at the 2nd Annual Sachs Cancer Bio Partnering and Investment Forum

Feb 25, 2014

PMV Pharma and Chiromics Announce Licensing Agreement and Drug Discovery Collaboration

Feb 20, 2014

Forbion Announces Closing of Public Offering of Portfolio Company, Argos Therapeutics

Jan 13, 2014

Madison Vaccines Closes $8 Million Series A Financing

Jan 9, 2014

FORMA Therapeutics Announces Advancement of Collaboration with Boehringer Ingelheim for Modulating Protein-Protein Interactions in the Treatment of Cancer

Jan 9, 2014

Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europe and Japan

Jan 9, 2014

Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept

Jan 9, 2014

DGAP-News: Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europe and Japan

Dec 16, 2013

CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment

Dec 5, 2013

Apogenix' APG350 Effectively Induces Apoptosis of Tumor Cells via TRAIL Pathway Independent of Fc-gamma Cross-Linking

Nov 21, 2013

Berg Launches First-Ever Stratified Medicine Clinical Trial To Investigate Cancer Metabolism Of Solid Tumors

Nov 11, 2013

Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma

Nov 8, 2013

Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD

Nov 5, 2013

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology

Nov 5, 2013

ADC Therapeutics Licenses Proprietary Antibodies From Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology

Nov 4, 2013

Hookipa Biotech Closes €20 Million ($27.5 Million) in Series B Financing

Nov 4, 2013

CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer

Oct 23, 2013

F-star Announces Formation of New Asset-Centric Vehicle, F-star Alpha Ltd, with €9.4m Series A investment

Oct 21, 2013

3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2013

TARIS Biomedical Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments

Oct 13, 2013

Bexion Pharmaceuticals Awarded $2.9MM SBIR Bridge Award by National Cancer Institute to Support Phase I First-in-Human Clinical Trial in Cancer

Aug 9, 2013

Berg Partners With Department of Defense Research Center and Military Medical Foundation to Advance Prostate Cancer Research

Jul 9, 2013

FORMA Therapeutics and Cancer Research Technology to Discover Cancer Drugs Targeting Deubiquitinating Enzymes (DUBs)

Jul 3, 2013

Blaze Bioscience and Fred Hutchinson Cancer Research Center Enter into Collaboration and Option Agreement in Support of Optides Discovery Program

Jun 19, 2013

Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma

Jun 17, 2013

Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer

Jun 16, 2013

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer

May 24, 2013

Research and Markets: Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors

Apr 6, 2013

Berg Research Provides New Insights into Potentially Novel Approaches for Detecting and Treating Cancer

Apr 4, 2013

Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

Mar 27, 2013

CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer

Mar 4, 2013

PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102

Feb 27, 2013

Blaze Bioscience Announces Two Poster Presentations at AACR-SNMMI Conference and Award of NCI SBIR Contract Advancing Tumor PaintTM Technology

Feb 4, 2013

KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101

Jan 2, 2013

Evotec and Apeiron Biologics Announce Collaboration on Cancer Immunotherapy

Dec 19, 2012

Sirnaomics Advances Its Novel siRNA Therapeutics Against HPV Infection and Cervical Cancer

Nov 5, 2012

UK Government Awards £1.7M Grant to PsiOxus Therapeutics for Second Phase I/II Clinical Trial of Cancer Vaccine

Oct 30, 2012

Complix Receives €1.9 Million IWT Grant to Accelerate Development Of Alphabodies™ against Intracellular Disease Targets, Including Cancer

Oct 23, 2012

DNAtrix and VectorLogics Complete Merger Transaction

Sep 7, 2012

The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer

Sep 6, 2012

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

Sep 5, 2012

FORMA Therapeutics Appoints Dr. Rob Sarisky to Chief Business Officer

Sep 5, 2012

ImmuNext Enters into a Strategic Partnership with Janssen to Develop Novel Immunotherapies for the Treatment of Cancer

Aug 9, 2012

Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program

Jul 6, 2012

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

Jun 28, 2012

Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients

Jun 19, 2012

Xcovery Appoints Expert in Targeted Cancer Therapeutics

May 24, 2012

PsiOxus Therapeutics Moves into New Facilities on Milton Park to Accommodate Expansion

Jan 10, 2012

FORMA Therapeutics Announces an Exclusive Cancer Drug Discovery Alliance Focused on Tumor Metabolism with Janssen Biotech, Inc.

Jan 5, 2012

FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs

Oct 18, 2011

Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products

Oct 11, 2011

Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies

Oct 3, 2011

National Cancer Institute Awards Gliknik Up to $1.5 Million in SBIR Funding

Sep 29, 2011

Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)

Sep 13, 2011

Teva Announces Additional Investment in CureTech

Aug 24, 2011

Cancer Prevention Pharmaceuticals Announces Completion of Bridge Financing Round

Aug 24, 2011

DGAP-News: Cancer Prevention Pharmaceuticals Announces Completion of Bridge Financing Round

Aug 23, 2011

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer

Jul 29, 2011

Cancer Prevention Pharmaceuticals Receives Positive Scientific Advice From EMA for CPP-1X Phase III TRIAL in FAP

Jul 29, 2011

DGAP-News: Cancer Prevention Pharmaceuticals Receives Positive Scientific Advice From EMA for CPP-1X Phase III TRIAL in FAP

Jul 27, 2011

Peloton Therapeutics Completes $18 Million Series A Financing

Jun 27, 2011

FORMA Therapeutics Grants Genentech Exclusive Rights to Acquire a Pre-clinical Cancer Program

Jun 22, 2011

Oncology Alliance: Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma

Mar 15, 2011

APEIRON Acquires Option to License Rights to Novel Oncology Compounds From Cleveland Clinic

Mar 7, 2011

Symphogen Receives US Patent on Lead Cancer Compound Sym004

Feb 1, 2011

Aphios Corporation Selected by SAIC-Frederick to Develop Camposomes™ in Support of the National Cancer Institute’s Alliance for Nanotechnology in Cancer

Dec 15, 2010

Myotec Therapeutics Completes Merger with Hybrid BioSystems to Form PsiOxus Therapeutics

Dec 1, 2010

Ascenta Therapeutics and Ascentage Pharma Sign R&D Collaboration and Regional License Agreements for Two Cancer Programs

Nov 30, 2010

The Leukemia and Lymphoma Society Provides Equity Financing to BioTheryX, Inc. to Accelerate Drug Development for Blood Cancer

Nov 3, 2010

EUSA Pharma Announces 10-Year Outcome Data Demonstrating Utility of PROSTASCINT(R) in Guiding Prostate Cancer Radiotherapy and Improving Disease-Free Survival

Oct 18, 2010

Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference

Oct 8, 2010

Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)

Jul 6, 2010

EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical

Jun 28, 2010

Emerald BioStructures and FORMA Therapeutics Enter Strategic Cancer Research Partnership

Feb 11, 2010

3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics

Jan 11, 2010

Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy of Anti–EGFR Monoclonal Antibody Combination Sym004

Jul 29, 2009

FORMA Therapeutics Announces Collaboration to Discover Inhibitors of Protein-Protein Interactions for Oncology

Jun 29, 2009

FORMA Therapeutics Appoints Kenneth W. Bair to Head Research and Development

May 20, 2009

IGF Oncology Announces Targeted Cancer Drug Results

Nov 6, 2006

Geron Licenses Antigen Targeting Patents for Cancer Vaccine Program from Immunomic Therapeutics